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Summary 
Background: Increasing evidence suggests that vitamin D may be protective in the 
development of cognitive impairment and dementia in older subjects. 
Objective: The overall objective was to examine the cross-sectional relationship 
between intake of vitamin D and cognitive performance.  
Design: The subjects (n=1916), aged 70-74 years, were recruited from the general 
population in Western Norway and underwent cognitive testing. The cognitive test 
battery included the Kendrick Object Learning Test, Trail Making Test part A, and 
modified versions of the Digit Symbol Test, Block design, Mini mental State 
Examination and Controlled Oral Word Association Test. Data on dietary habits were 
collected via a food frequency questionnaire. Poor cognitive performance was defined 
as the lowest 10th percentile for all of the tests, except the TMT-A were the 90th 
percentile was used as a cut-off. 
Results: Sixty-four percent of the population did not meet the Nordic 
recommendations of vitamin D intake (≥10 µg/d). Of those that took cod liver oil as a 
supplement, 76.1% reached the recommended intake of vitamin D. Fish was the most 
important food source of vitamin D contributing with 38.3% of the total intake of 
vitamin D. Multivariate linear regression analyses showed that the S-task (verbal 
fluency) and KOLT (episodic memory) were significantly associated with intake of 
vitamin D. Logistic regression analyses showed that the risk of scoring poorly on the 
KOLT was significantly increased when the intake of vitamin D was low (≤3.57µg/d) . 
Intake of cod liver oil was not associated with KOLT score. For non-users of cod liver 
oil the risk of scoring poorly on the KOLT increased when the intake of lean fish was 
low (0.1 g/d – 25.0 g/d, P = 0.027). 
Conclusions: In the present population consisting of elderly from the western part of 
Norway, cod liver oil supplementation was effective in achieving recommended intake 
levels of vitamin D. Even though the population had a high intake of vitamin D-
containing foods compared to other studies, a high proportion of the individuals were 
not able to meet the Nordic recommendations (≥10 µg/d). A diet low in vitamin D was 
associated with a lower score on a verbal fluency test as well as an episodic memory 
test. In non-users of cod liver oil, episodic memory was negatively affected by a low 
intake of lean fish. Fish as a food item or dietary pattern may be more protective when 
it comes to cognitive decline than vitamin D as a single nutrient. 
 
Table of contents 
ACKNOWLEDGEMENTS ................................................................................................................. 4 
SUMMARY .......................................................................................................................................... 5 
TABLE OF CONTENTS ..................................................................................................................... 7 
TABLES .............................................................................................................................................. 10 
FIGURES ............................................................................................................................................ 12 
APPENDICES .................................................................................................................................... 13 
ABBREVIATIONS ............................................................................................................................ 14 
1. INTRODUCTION ................................................................................................................... 17 
1.1 VITAMIN D ............................................................................................................................ 17 
1.1.1 Bioactivation .............................................................................................................. 17 
1.1.2 Transport of vitamin D ............................................................................................... 18 
1.1.3 Functions of vitamin D ............................................................................................... 18 
1.2 VITAMIN D AND THE ELDERLY .............................................................................................. 20 
1.2.1 Recommendations ...................................................................................................... 20 
1.2.2 Vitamin D status and intake ....................................................................................... 21 
1.2.3 Challenges .................................................................................................................. 23 
1.3 VITAMIN D AND COGNITION .................................................................................................. 23 
1.3.1 Clinical evidence ........................................................................................................ 24 
1.3.2 Biological evidence .................................................................................................... 24 
1.3.3 Vitamin D in relation to dementias ............................................................................ 26 
1.4 RATIONALE OF THE THESIS .................................................................................................... 28 
2. OBJECTIVES .......................................................................................................................... 29 
3. STUDY POPULATION AND METHODS ........................................................................... 30 
3.1 STUDY POPULATION............................................................................................................... 30 
3.2 DATA COLLECTION ................................................................................................................ 32 
3.2.1 Dietary habits ............................................................................................................. 32 
3.2.2 Cognitive tests ............................................................................................................ 34 
3.2.3 Other variables ........................................................................................................... 37 
3.3 STATISTICAL ANALYSES ........................................................................................................ 38 
4. RESULTS ................................................................................................................................. 43 
4.1 DIETARY INTAKE ................................................................................................................... 43 
4.2 COGNITIVE PERFORMANCE .................................................................................................... 47 
4.3 ADEQUATE VS. LOW INTAKE OF VITAMIN D ........................................................................... 47 
4.4 UNADJUSTED ANALYSES INCLUDING STUDENT’S T-TESTS AND SIMPLE CORRELATIONS ......... 50 
4.5 LINEAR REGRESSION ANALYSES ............................................................................................ 54 
4.6 RISK OF POOR COGNITIVE TEST PERFORMANCE ACCORDING TO VITAMIN D INTAKE ............... 56 
4.7 INTAKE OF COD LIVER OIL, LEAN FISH AND FATTY FISH IN RELATION TO SCORING POORLY ON AN EPISODIC 
MEMORY TEST (KOLT) ................................................................................................................... 58 
5. DISCUSSION ........................................................................................................................... 62 
5.1 METHODOLOGICAL CONSIDERATIONS .................................................................................... 62 
5.1.1 Study design ............................................................................................................... 62 
5.1.2 Statistical aspects ....................................................................................................... 63 
5.1.3 Bias and confounding ................................................................................................. 63 
5.1.4 Generalisation ............................................................................................................ 67 
5.2 DISCUSSION OF SPECIFIC RESULTS ......................................................................................... 68 
5.2.1 Intake of vitamin D in the elderly ............................................................................... 68 
5.2.2 Intake of vitamin D and cognitive test performance .................................................. 70 
5.2.3 Intakes of cod liver oil, lean fish and fatty fish in relation to cognitive performance 72 
6. CONCLUSIONS AND IMPLICATIONS .............................................................................. 75 
REFERENCES ................................................................................................................................... 76 
ARTICLE ........................................................................................................................................... 85 
APPENDICES .................................................................................................................................. 128 
  
Tables 
Table 1 The Nordic Recommendations for vitamin D intake 
Table 2 Intake of vitamin D according to a Norwegian nationwide survey 
Table 3 Mechanisms whereby vitamin D metabolites protect the brain  
Table 4 Sources of vitamin D, the mean contribution of each source, and intake 
of the food group in the total population 
Table 5 Sources and their mean contribution of vitamin D divided into users/non-
users of cod liver oil 
Table 6 Number of users- and non-users of cod liver oil according to the Nordic 
recommendations of vitamin D 
Table 7 Vitamin D intake classified by the use of cod liver oil 
Table 8 Cognitive performance 
Table 9 Adequate vs. low intake of vitamin D 
Table 10 Students t-test for dichotomous variables for the cognitive tests and 
vitamin D intake 
Table 11  Spearman’s Rho correlation coefficients between continuous variables, 
the cognitive tests and vitamin D intake 
Table 12 Linear regression analysis showing the relationship between vitamin D 
intake and the different cognitive tests 
Table 13 Binary logistic regression analyses 
Table 14 Linear regression analyses exploring the relationship between intakes of 
cod liver oil, fatty fish, lean fish and KOLT score 
Table 15  Logistic regression analysis exploring the relationship between intakes of 
lean fish and fatty fish, in users and non-users of cod liver oil, in regards 
to scoring poorly on the KOLT. 
Table 16 Logistic regression analysis exploring the relationship between intake of 
lean fish and fatty fish in users and non-users of cod liver oil in regards to 
scoring poorly on the KOLT. Multiple adjustments 
 
 
Figures 
Figure 1 Recruitment in HHS and HUSK 
Figure 2 Bio-activation of vitamin D 
Figure 3 Histograms showing the distributions of the cognitive tests 
Figure 4 Histogram showing the distribution of Vitamin D intake in the total 
population 
Figure 5 Histograms showing the distributions of vitamin D intake in users and 
non-users of cod liver oil 
Appendices 
Appendix I  Consent form 
Appendix II  Hordaland Health Study; questionnaire 1 
Appendix III  Invitation letter 
Appendix IV  Hordaland Health Study; food frequency questionnaire 
Appendix V  Hordaland Health Study; cognitive testing 
Appendix VI  Hospital Anxiety and Depression Scale 
Abbreviations 
25(OH)D  25-hydroxyvitamin D (Cholecalciferol, vitamin D3) 
1,25(OH)2D3  1,25-dihydroxyvitamin D (Calcitriol) 
ApoE   Apolipoprotein E 
BMI   Body Mass Index 
CI   Confidence Interval 
CVD   Cardiovascular disease 
DBP   Vitamin D binding protein 
FFQ   Food Frequency Questionnaire 
HADS  Hospital Anxiety and Depression Scale 
HHS   Hordaland Homocysteine Study (1992-1993) 
HUSK  Hordaland Health Study (1997-1999) 
iNOS   Inducible nitric oxide synthase 
IU   International Unit 
kJ   Kilo Joules 
KOLT  Kendrick Object Learning Test 
m-BD   Modified version of the Block Design test 
m-DST  Modified version of the Digit Symbol test 
m-MMSE  Modified version of the Mini Mental State Examination 
NNR   Nordic Nutrition Recommendation 
OR   Odds Ratio 
PAL   Physical activity level 
PTH   Parathyroid hormone 
PUFA   poly-unsaturated fatty acid 
RDA   Recommended Daily Allowance 
S-task Abridged version of the Controlled Oral Word Association 
(COWAT) 
SD   Standard Deviation 
SE   Standard Error 
tHcy   Total homocysteine 
TMT-A  Trail Making Test part A 
VDR   Vitamin D receptor 
VDR-KO  Vitamin D receptor knock-out 
Vitamin D2  Ergocalciferol  
UV   Ultra violet 
 
1. Introduction 
1.1 Vitamin D 
1.1.1 Bioactivation 
Vitamin D is a pro-hormone that is produced in the skin through a photolytic process 
induced upon exposure to sunlight (UVB 290-320 nm) [1]. There are two types of 
vitamin D; cholecalciferol (D3) and ergocalciferol (D2). Vitamin D3 is produced in the 
skin, whereas vitamin D2 is derived from plants and yeast. In the production of vitamin 
D3, 7-dehydrocholesterol in cell membranes is converted to pre-vitamin D3, which is 
then slowly converted to vitamin D3 [2]. The bio-activation of vitamin D starts in the 
liver where vitamin D is hydroxylated at carbon 25 by 25-hydroxylase (a hepatic 
cytochrome P-450) (Figure 1). The hydroxylation reaction is poorly regulated and the 
levels of 25(OH)D increase in proportion to vitamin D intake [3]. For this reason, in 
addition to having a long half-life (3 weeks) 25(OH)D is used as an indicator for 
vitamin D status [1]. After formation of 25(OH)D has taken place, the formation of 
1,25(OH)2D3 (calcitriol) occur in the kidney through the action of 1α-hydroxylase [4] 
(Figure 1). The high potency of 1,25(OH)2D3 in elevating serum calcium and 
phosphate levels requires a mechanism to stop its activity. This is accomplished within 
more or less all target cells by the 1,25(OH)2D3-inducible vitamin D 24-hydroxylase 
[4]. 
 
Figure 1. Adapted from Dusso et al. 2005 
1.1.2 Transport of vitamin D 
Vitamin D metabolites are lipophilic molecules with low aqueous solubility that are 
transported in the circulation bound to plasma proteins [4]. The most important of 
these carrier proteins is the vitamin D binding protein (DBP). Plasma levels of DBP 
are 20 times higher than the total amount of vitamin D metabolites [5], and the 
majority of 25(OH)D and 1,25(OH)2D3 are bound to DBP (80-90%) and albumin (10-
20%), while a tiny fraction is free in plasma [6]. 
Entry of 25(OH)D into the proximal tubule cells in the kidneys is not by diffusion 
across the basolateral surface but by receptor-mediated uptake of DBP in the brush 
border [7]. Once inside the cells, DBP is degraded, releasing 25(OH)D for metabolism 
by 1α-hydroxylase or 24-hydroxylase [8]. 
1.1.3 Functions of vitamin D 
Vitamin D has several different functions in the body. They are usually classified into 
genomic and non-genomic actions and classical and non-classical functions. 
Genomic actions 
Most of the biological activities of 1,25(OH)2D3 require a high-affinity receptor, the 
vitamin D receptor (VDR), a member of the superfamily of nuclear receptors for 
steroid hormones [9]. Like the other members of the steroid receptor family, the VDR 
acts as a ligand-activated transcription factor [10]. The major steps in which VDR 
regulate gene transcription include ligand binding to the ligand binding domain of the 
VDR, heterodimerization with retinoic X receptor, binding of the heterodimer to the 
vitamin D responsive element in the promoter region of vitamin D responsive gene, 
and recruitment of VDR-interacting nuclear proteins into the transcriptional pre-
initiation complex [10]. This process ultimately results in either an enhancement or a 
suppression of the rate of gene transcription by the VDR [11].  
Non-genomic actions 
The active form of vitamin D can also bring forth responses that are too rapid to 
involve changes in gene expression. These responses appear to be mediated by cell 
surface receptors and second messengers [4]. 1,25(OH)2D3 can rapidly stimulate 
phosphoinositide metabolism, cytocolic calcium levels, cGMP levels, PKC, MAP 
kinases and the opening of chloride channels [9, 12]. Although animal experiments 
have shown that 1,25(OH)2D3 can induce immediate responses in several different cell 
types, the pathways to which these responses occur remains to be identified [4]. 
Classic functions of vitamin D 
Vitamin D is essential for promoting calcium absorption in the gut and maintaining 
adequate serum calcium and phosphate concentrations to enable normal mineralisation 
of bone and also to prevent hypocalcemic tetany [4]. For this reason, rickets in children 
and osteomalacia in adults are clinical manifestations of vitamin D deficiency [13]. 
Furthermore, it is needed for bone remodelling, and protects against osteoporosis in 
older adults [14]. 
Together with parathyroid hormone (PTH) vitamin D keep calcium levels in serum 
constant by three mechanisms. Firstly, vitamin D induces transcription of genes that 
are involved in active intestinal calcium absorption. Secondly, vitamin D mobilises 
calcium from bones when calcium is not available from the gut. Thirdly, vitamin D 
stimulates the kidneys (distal renal tubule) to reabsorb 1% of the filtered load of 
calcium (7 g of calcium are filtered through the kidneys everyday) [2]. 
When serum levels of calcium decline, it stimulates the production and secretion of 
PTH from the parathyroid gland. PTH then stimulates 1α-hydroxylase in the kidney 
which in turn increases the production of 1,25(OH)2D3. 1,25(OH)2D3 then increase the 
calcium concentrations by the three aforementioned mechanisms. 1,25(OH)2D3 inhibits 
PTH synthesis and parathyroid cell growth via direct transrepression of the PTH gene 
by the 1,25(OH)2D3-VDR complex [4]. 
Non-classic functions of vitamin D 
In more recent years, it has been well established that vitamin D is important for 
diseases that are not related to calcium homeostasis. Wang published a review that 
focused on ecological, case-control and cohort studies where the role of vitamin D in 
health and disease were explored. Of disorders not related to calcium homeostasis they 
highlighted the possible function of vitamin D in muscles, autoimmune diseases, type 2 
diabetes, cardiovascular diseases and cancer [1]. Furthermore, the understanding of the 
underlying mechanisms in which vitamin D exerts its effects on these diseases is 
growing with an increasing body of evidence [4]. 
1.2 Vitamin D and the elderly 
1.2.1 Recommendations 
Requirement of a nutrient is the lowest amount needed to avoid clinical symptoms 
while recommended intake includes a security margin to account for individual 
variability and uncertainties in the data [15]. Generally, the unfavourable effects of low 
plasma 25(OH)D begin to accumulate at levels below 50 nmol/L, although some 
studies have suggested higher threshold levels. Lips et al proposed that levels below 50 
nmol/L should be defined as insufficiency, levels below 25 nmol/L should exemplify 
deficiency and levels below 12 nmol/L should be characterised as severe deficiency 
[16]. Levels between 25 and 12 nmol/L may cause proximal myopathy or increased 
bone turnover, whereas levels below 12 nmol/L are frequently present in individuals 
with rickets and osteomalacia [17]. 
The different threshold levels used by different researchers make the use of the words 
“deficiency” and “insufficiency” somewhat arbitrary. In the present thesis the terms 
“insufficiency” and “deficiency” are defined according to Lips’ previously mentioned 
suggestion unless otherwise stated. 
To ensure an acceptable vitamin D status in the population, the recommended dietary 
intake of vitamin D according to the Nordic Nutrition Recommendations 2004 is 10 
μg/d for the age groups 6-23 months and above 61 years and 7.5 μg/d for all other age 
groups (Table 1) [18]. 
Table 1. Nordic recommendations according to sex and age groups 
Vitamin D (µg/d) 
Age Children Men Women 
6 - 23 months 10   
2 - 9 years 7.5   
10 - 60 years  7.5 7.5* 
≥ 61 years   10 10 
* 10 µg for lactating and pregnant women 
 
Compared to the previous edition of NNR, the recommendation for the age groups 2–
60 years has been increased by 50% from 5 µg/d to 7.5 µg/d; this is in order to 
diminish the seasonal drop in plasma 25(OH)D during the winter months [15]. 
1.2.2 Vitamin D status and intake 
The prevalence of vitamin D deficiency is high in the elderly population [16], and it 
has been estimated that 40-90% of the elderly worldwide have vitamin D insufficiency 
(≤75 nmol/L) [19]. 
Lips et al report that vitamin D insufficiency is a common finding among community-
dwelling elderly, and almost an exclusive finding among institutionalized elderly [16, 
17]. In the USA however, vitamin D status amongst the elderly is more acceptable, 
probably a result of liberal fortification politics [20]. 
The Nordic countries cover latitudes from approximately 54° N in Denmark to 72° in 
northern Norway [21]. It has been reported that people living in high latitudes often 
have a reduced endogenous production of vitamin D as the UV wavelengths are less 
than optimal for dermal production of the vitamin [22]. An adequate intake to 
compensate for this issue is therefore of particular relevance to populations in the 
Nordic countries. 
In Denmark, 80% of elderly over 65 years had vitamin D insufficiency and  44% of 
nursing home residents had severe vitamin D deficiency [23]. Mosekilde et al found 
that there was a strong seasonal variation in serum 25(OH)D in a Danish population. 
The results showed a marked downward shift during the winter months, with levels 
falling well below desirable vitamin D status in a large part of the population [23]. 
Lips et al found however that within Europe, serum 25(OH)D was positively related to 
latitude, contrary to what would be expected [16]. The highest serum 25(OH)D levels 
were observed in Scandinavian countries and the lowest levels were found in Southern 
Europe. They speculate that this may be due to high sun exposure, a light skin and 
multivitamin use in northern countries while shadow-seeking behaviour and a darker 
skin tone are more common in Mediterranean countries [16].  
A study from Finland showed that participants had a satisfactory vitamin D status 
during summer, whereas a large portion of the subjects had a poor vitamin D status 
during the months of winter [24]. More adequate serum levels of 25(OH)D were found 
in a similar study from Tromsø [25]. One explanation for the disparity observed in 
vitamin D status between the two population groups during the winter months is that, 
at the time of these studies, the intake of fish/fish products and margarine fortified with 
vitamin D was a lot higher in Norway than in Finland [15]. 
Data from the National Nutrition Council from 2006 indicate that the intake for the 
elderly population in Norway is very low compared to the recommended intake (Table 
2) [15, 26]. Furthermore, it appears as though supplementation is very important for 
the total intake of vitamin D. 
Table 2. Intake of vitamin D according to a Norwegian nationwide survey 
(Norkost 1997) 
Age group n Vitamin D without  Vitamin D with  Below recommended 
    supplemntation (µg/d)1 supplementation (µg/d)  intake (%) 
60 - 79 years     
Women 246 4.0 (2.2) 12.5 (10.8) 47 
Men 237 5.8 (3.8) 13.9 (11.0) 48 
1 Mean (SD). All such values   
 
1.2.3 Challenges 
The elderly population is at increased risk of developing vitamin D deficiency for a 
number of reasons. Both biological and behavioural issues make this population 
particularly vulnerable. Such factors can be disadvantageous on their own or, more 
expectedly synergistic. 
The biological factors that contribute to the increased risk of a poor vitamin D status in 
the elderly are a reduced capacity to synthesise the vitamin in the skin, in addition to a 
decrease in the renal production of 1,25(OH)2D3 as a result of diminishing renal 
function with age [27, 28]. Holick et al found a >4-fold difference in elevation of 
serum cholecalciferol level induced by standard skin exposure to UVB radiation in 
individuals aged 62-80, as compared to 20-30 year old controls [29]. 
Behavioural factors that add to the risk of having a poor vitamin D status in the elderly 
population are many. They are, however, easily modifiable (at least in theory). Elderly 
that are institutionalised have been shown to have a very poor vitamin D status, a result 
of getting little, if any, exposure to sunlight [29]. Another factor related to sunlight 
exposure is that elderly usually cover themselves up more than adolescents [30]. The 
use of sunscreens and the fact that the larger part of the modern population work 
indoors during the hours when the dermal production of vitamin D in response to solar 
radiation is at its maximum, contribute to the reduced production of vitamin D in the 
skin [30]. 
1.3 Vitamin D and Cognition 
Dementia is the progressive decline in cognitive function due to the presence of 
disease or damage in the brain [31]. The pathology of dementia is complex and may 
involve a number of mechanisms including oxidation, inflammation, disease induced 
neurotoxicity, and genetic vulnerability [32-34]. Alzheimer’s type dementia and 
vascular dementia are the most common forms of age-associated dementia [32]. Ferri 
et al reviewed evidence from epidemiological studies and estimated that 24.3 million 
people have dementia today, with 4.6 million new cases of dementia every year (one 
new case every 7 seconds). They go on to say that the number of people affected will 
double every 20 years to 81.1 million by 2040 [35]. Alzheimer's disease is the sixth 
leading cause of all deaths in the United States [36].  
1.3.1 Clinical evidence 
Several studies have shown an association with Vitamin D in serum and cognitive 
decline [37-40]. These, however, are observational studies, and so far evidence based 
on randomized clinical trials is lacking. Furthermore, several studies have found no 
relationship between serum vitamin D concentrations and cognition [41, 42]. A review 
article by Annweiler et al reviewed 5 cross-sectional studies that had looked into the 
relationship between serum 25(OH)D and cognition found the evidence to be 
inconclusive [43].  
The biological plausibility for an association between vitamin D and cognition is 
however well supported [44]. 
1.3.2 Biological evidence 
VDR polymorphisms 
The vitamin D receptor (VDR) is highly expressed in regions of the brain that is 
affected in conditions that is related to cognitive impairment [45]. The VDR gene 
contains several polymorphisms of which five; Cdx-2, FokI, BsmI, ApaI and TaqI, 
have been most frequently investigated [46]. These have been associated with a 
number of phenotypes, such as bone mineral density, and risks for fractures and cancer 
[11]. In addition, haplotype alleles have been identified that influence the risk of 
osteoporotic fractures and the expression of the VDR gene [47, 48]. The risk 
haplotypes that have recently emerged, baT and BAt, are composed of the BsmI, ApaI 
and TaqI polymorphisms [46]. 
It has been shown that animals exposed to prenatal vitamin D deficiency have 
alterations in brain morphology [49], locomotion [50], and learning and memory [51]. 
In addition, mice lacking a functional VDR gene appear to suffer from anxiety-like 
behaviour [52, 53]. 
Kuningas et al concluded that genetic variance in the VDR gene influences the 
susceptibility to age-related changes in cognitive functioning and in depressive 
symptoms [46]. The study was carried out in the prospective population-based Leiden 
85-plus Study. Participants of the study were genotyped for Cdx-2, FokI, BsmI, ApaI 
and TaqI polymorphisms in the VDR gene. The data revealed an overall worse 
performance on tests measuring cognitive functioning for carriers of BsmI and TaqI 
polymorphisms, and of haplotype BAt. In contrast, carriers of ApaI variant-allele and of 
haplotype baT had better cognitive functioning together with less depressive 
symptoms. Furthermore, they make a point of saying that the associations discovered 
in the study could not be explained by differences in calcium levels or by selective 
survival, since no associations between the VDR gene variants and calcium levels and 
mortality were observed [46]. 
Neuronal protection 
Studies have shown that protection of the structure and integrity of neurons through 
detoxification pathways as well as neurotrophin synthesis are both processes in which 
vitamin D is involved [54-58]. 
The enzyme inducible nitric oxide synthase (iNOS) is inhibited by 1,25(OH)2D3. This 
enzyme is up-regulated during ischemic events and in patients with Alzheimer’s 
disease [59]. 
1,25(OH)2D3 boost innate antioxidant pathways. Gamma glutamyl transpeptidase is 
up-regulated by the active hormone which consequently leads to an increase in 
glutathione [60]. Glutathione is an innate antioxidant which protects oligodendrocytes 
and the nerve conduction pathway vital to mental processing [31]. 
Neurotrophins (NT) are proteins necessary for neuronal survival in aging and 
neuropathological conditions [61]. When neurotrophin synthesis is decreased, spatial 
navigation is compromised [61]. 1,25(OH)2D3 up-regulates protective neurotrophin 
factors, such as neurotrophin-3 (NT-3) and glial cell line derived neurotrophic factor 
(GDNF) [54, 55]. NT-3 protects nerve transmission and synapticity [56-58] [61]. 
GDNF affects the survival and differentiation of dopaminergic cells [31].  
Co-localisation of VDR and 1,25(OH)2D3 in the brain 
Evidence supporting a ligand mediated VDR pathway in the human brain is a recent 
finding. 
An early study of patients with Alzheimer’s disease revealed the presence of VDR 
mRNA in humans [62], yet the presence and accessibility of 1,25(OH)2D3, necessary 
for activation of the nuclear pathway, remained unclear [31]. 
Neuronal and glial cells, cerebral purkinje cells and cells in the cerebral cortex are 
particularly vulnerable to age and degeneration related to disease [31]. Biosynthetic 
and degradative pathways for 1,25(OH)2D3 have been discovered in the 
abovementioned cell types [54, 55, 63, 64]. 
A study of human brains confirmed the presence of the VDR as well as genes encoding 
catalytic enzymes in 1,25(OH)2D3 metabolism in both neuronal and glial cells within 
brain structures critical for cognition [45, 50, 64]. Furthermore, the VDR and catalytic 
enzymes were co-localized in the brain. These findings support a functional role for 
vitamin D in the human brain [31]. 
1.3.3 Vitamin D in relation to dementias 
Vascular dementia 
Vitamin D may help improve vascular-related brain disease by attenuating damaging 
effects of calcium dysregulation, increased oxidative stress and inflammation [44]. 
Hippocampal cell loss and neuronal ageing, both of which are important in 
neurodegenerative diseases, have been attributed to elevated L-type voltage calcium 
channel density and glucocorticoid neurotoxicity [65]. Studies have shown that vitamin 
D mediate regulatory benefits in neuronal calcium homeostasis and protects neurons 
from excess calcium entry in the brain [66]. These beneficial changes protect brain 
neurons during ischemic events. 
Neurotrophins are proteins necessary for neuronal survival in aging and 
neuropathological conditions [61]. 1,25(OH)2D3 up-regulates protective neurotrophin 
factors, such as neurotrophin-3 and glial cell line derived neurotrophic factor [54, 55]. 
Both up-regulation of glial cell line derived neurotrophic factor and the increase in 
innate antioxidative defences have been shown to attenuate ischemic brain disease in 
rodents [67]. 
Vascular related brain damage may result from inflammatory responses. Vitamin D 
inhibits antigen-presenting cell maturation, down regulates NF-κB and stimulates anti-
inflammatory cytokine production [68-70], and so acts as an anti-inflammatory agent. 
Epidemiological studies have found an inverse relationship between vitamin D and C-
reactive protein levels, a marker of inflammation [70]. 
Vitamin D may play a role in protection against cardiovascular and cerebrovascular 
disease [71-73]. Intervention with vitamin D has been shown to regulate blood 
pressure, cardiac hypertrophy, and plasma renin activity [74-78]. It is reasonable to 
believe that vitamin D may influence vascular-related dementia via these indirect 
mechanisms [31, 44]. 
Alzheimer’s disease 
Hippocampal neuronal loss is a characteristic finding in Alzheimer’s disease. 
Treatment with 1,25(OH)2D3 attenuated hippocampal atrophy and protected neuron 
density in aging rats [79].  
Data in human subjects with Alzheimer’s disease revealed a reduction in VDR mRNA 
in specific regions of the hippocampus compared to controls [62] and a higher 
frequency of VDR polymorphisms were found in Alzheimer’s brains than in age-
matched controls [80].  
Table 3 summarises the mechanisms whereby vitamin D metabolites may protect the 
brain. 
 
Table 3. Mechanisms whereby vitamin D metabolites may protect the brain 
Factor Mechanism  
Neuronal protection Inhibition of iNOS 
 Enhances antioxidant pathways. 
 Upregulates neurotrophin factors. 
  
Neronal calcium regulation Protects against excess calcium entry into the brain. 
  
Reduction of inflammatory factors Inhibits antigen presenting cell maturation 
 Down regulates NF-κB 
 Stimulates anti-inflammatory cytokine production 
  
Vasculoprotection Regulates blood pressure 
 Regulates of cardiac hypertrophy 
  Regulates plasma renin activity 
Adapted from W.B. Grant 2009 Does Vitamin D reduce the Risk of Dementia? 
1.4 Rationale of the thesis 
As the population’s lifespan increase, so does the prevalence of different dementias 
and cognitive deficits. It is of great interest to find preventative strategies for this 
disease to relieve both the financial burden on society, and the emotional burden 
experienced by the patient and his or her surrounding family. 
In the January issue of Neurology 2010, it was stated in the editorial that “… more 
research (in regards to vitamin D and cognition) needs to be performed in both men 
and women living in the community (…) Patients with vitamin D deficiency should be 
given more cognitive testing to see which aspects of their thinking are affected.” 
 
 
2. Objectives 
Elderly are at particular risk for developing vitamin D deficiency. The present study 
focuses on the intake of vitamin D in relation to cognition in older subjects using data 
from the Hordaland Health Study, a population with a high intake of fish and fish oils. 
The objective was to examine the cross-sectional relationship between intake of 
vitamin D and cognitive performance. 
The specific aims of the study were: 
To describe the sources of vitamin D in the study population  
To investigate the effect of cod liver oil on intake of vitamin D in the study population  
To study the association between intake of vitamin D and cognitive function, including 
poor cognitive function in the study population 
To study the intake of cod liver oil, lean fish and fatty fish in relation to cognition in 
the study population 
 
3. Study population and methods 
3.1 Study population 
The baseline examination of the Hordaland Homocysteine Study (HHS) was conducted 
in the Hordaland County of Western Norway from April 1992 to April 1993 as a 
collaboration between the national health screening service, local health services and 
the University of Bergen. The eligible subjects were selected from the national 
population registry, identified by place and residence and age on December 31, 1992. 
A total of 24 815 subjects from three age groups were invited. The youngest age group 
included all subjects in the county who were born in 1950, 1951 or 1952 (40-42 years 
of age at the time of data collection). The older age group covered all subjects born in 
1925, 1926 and 1927 (65-67 years at the time of data collection) residing in Bergen 
and three neighbouring suburban municipalities. A third group born between 1925 and 
1949 (43-65 years) was a 2% random sample of residents in Bergen. The overall 
attendance rate was 72.7% (N = 18 044). In the Hordaland Health study (HUSK), 
performed in 1997-99, a selection of the youngest age group and all of the living 
participants of the older age group were re-invited. A total of 9187 individuals were re-
invited, and the overall attendance rate was 77.0 % (N = 7074). The number of elderly 
re-invited in HUSK to examine age effects was 4338 in which 3341 took part in the 
study. Recruitment into the Cognitive Substudy is described on the Web (Internet: 
www.uib.no/isf/husk/Vedlegg_dokumenter/Cognitive_Sub_study.pdf). A total of 2155 
subjects completed the cognitive test battery. Of those, 1991 individuals completed a 
food-frequency questionnaire. Participants with a very low energy intake (< 3000 kJ 
for women < 3300 for men), or very high energy intake (≥ 15000 kJ for women; ≥ 
17500) for men were excluded from the analyses (Berstad, Konstantinova et al. 2007), 
leaving a total of 1916 subjects in this study on cognition and vitamin D intake. All 
participating subjects gave their written informed consent (Appendix I). The study 
protocol was approved by the Regional Committee for Medical Research Ethics of 
Western Norway. Recruitment in HHS and HUSK is depicted in Fig 1. 
Figure 1. Recruitment in HHS and HUSK 
 
 
3.2 Data collection 
The study included three self-administered questionnaires, two of which are relevant to 
the present thesis. Briefly, the main 4-page questionnaire (Appendix II) used by the 
National Health Screening Service was sent together with the invitation letter 
(Appendix III), filled out at home, collected and checked for errors by a nurse at the 
examination day. Information included parity, physical activity, smoking, consumption 
of coffee and alcohol, education as well as current use of prescription and over-the-
counter medications. Usual dietary habits during the last year were assessed by a 
comprehensive 169-item food frequency questionnaire (FFQ) (Appendix IV). The 
questionnaire was developed at the section for dietary research, Department of 
Nutrition research at the University of Oslo. It was handed out at the examination day, 
filled out at home and mailed to the HUSK project centre in Bergen. 
Cognitive testing was performed at the study location by trained nurses after the 
standard cardiovascular examinations of the National Health Screening Service were 
completed. The cognitive test battery included 6 tests (Appendix V). 
Baseline measurements included height, weight, waist and hip circumference, blood 
pressure, heart rate, non-fasting analyses of serum total cholesterol, HDL-cholesterol, 
triglycerides, and glucose. Nonfasting EDTA blood samples was collected for the 
measurement of total homocysteine (tHcy), related B vitamins, creatinine and gene 
polymorphisms. 
3.2.1 Dietary habits 
The intake of vitamin D was self-reported and estimated using data from an FFQ. The 
FFQ has been validated by several studies [81-85]. 
The FFQ included 169 food items that were grouped according to Norwegian meal 
patterns. It was designed to obtain information on usual food intake during the past 
year. The frequency of consumption was given per day, week, or month. The portion 
sizes were given as household measures, or units such as slices or pieces. In addition to 
food groups the questionnaire also included questions about dietary supplement intake, 
in which the product names of the most used supplements in Norway were considered. 
The subjects were advised to estimate an “average” of amounts of food. 
The intake of vitamin D per person according to food group was calculated by the use 
of a food database and software system developed at the Department of Nutrition, 
University of Oslo (Kostberegningssystem, KBS, version 3.2; University of Oslo, 
Oslo, Norway) [82].  
Fish and fish products, supplements, butter and margarines, eggs and dairy products 
are sources that contribute to the total vitamin D intake in the Norwegian population. 
Butter and margarines as well as some dairy products are fortified with vitamin D. Fish 
and fish products were reported as dinner dishes or bread spreads (sandwich fillers). 
Dinner items were reported as how many times the food item was consumed per month 
and amount of food per consumption. Entities differed according to food item 
depending on what was appropriate for the specific food in question (e.g. piece, fillet, 
dL etc). The items in the fish category were fishcakes, fish pudding or fish balls, fish 
fingers, cod, coalfish, or haddock (either poached or fried), mackerel, salmon, trout, 
fish stew/soup/gratin, or shrimp/crab. As bread spreads the amount of food item was 
reported as number of slices of bread needed for the amount of bread spread pr week. 
The food items were caviar, mackerel in tomato paste/smoked mackerel, 
sardines/pickled herring/anchovies, salmon/trout and shrimp/crab. Use of supplements 
was reported as “seasonal use” (during the whole year or only winter half of the year), 
frequency per week, and amount per time. Eggs were reported as how many eggs per 
week. Types of egg dishes included boiled, fried, scrambled or as an omelette. Dairy 
products that contain vitamin D was recorded as milk as a drink with amounts as 
number of glasses per day, and for cheese as bread spreads as well as cheese on pizza. 
There are three questions regarding the use of butter and margarine including the use 
of these products as a bread spread, use in cooking in general, and as a dinner 
supplement. In the question dealing with fat as a bread spread it was asked what 
product was preferred, and if it was used both in the weekdays and the weekend. There 
was also a question that asks how many slices of bread a 12 g pack of butter would last 
to get an impression of the amount the individual was using. In the “cooking in 
general” question it was asked which product was preferred, but there was no question 
regarding the amount. As a dinner supplement melted butter/margarine was an option. 
Amount was given in table spoons. 
The calculated intake of vitamin D from the individual food groups showed that cakes 
and cookies, potato and vegetables had limited amounts of vitamin D. Cakes and 
cookies had vitamin D from butter/margarines, as did potatoes (french fries) and 
vegetables (fried onions). These variables were for that reason added to the 
butter/margarines group. The food group “Cereals” include flour, rice pasta, pizza and 
breakfast cereals and had small amounts of vitamin D from the pizza group that 
contains cheese. Vitamin D from “Cereals” was therefore added to the “Dairy 
products” variable. The food groups “Fruit” and “Juice” were also added together. The 
combining of variables did not change the results in the final analyses. 
3.2.2 Cognitive tests 
In the present study, the following cognitive tests were used: The abridged version of 
the Controlled Oral Word Association test (S-task), the Kendrick Object Learning test 
(KOLT), the modified version of the Digit Symbol Test (m-DST), the Trail Making 
Test Part A (TMT-A), the modified version of the Block Design test (m-BD), and the 
modified version of the Mini Mental State Examination (m-MMSE) which is a global 
cognitive test. A sum Z-score variable was calculated by adding together the Z-scores 
from all the cognitive tests with the exception of the m-MMSE. The sum Z-score 
represents global cognition, but unlike the m-MMSE has the advantage of being 
normally distributed, without ceiling effect. 
The Controlled Oral Word Association Test 
The controlled oral word association test is a test of verbal fluency (access to semantic 
memory and psychomotor speed) consisting of three word naming trials. The set of 
letters that was first employed, FAS, has been used so extensively that this test is 
sometimes called FAS [86]. Words beginning with the first letter of the set have a 
relatively high frequency. The second letter has a somewhat lower frequency, and the 
third letter has a still lower frequency. To give the test, the examiner asks subjects to 
say as many words as they can think of that begin with the given letter of the alphabet, 
excluding proper nouns, numbers, and the same word with a different suffix. The score 
is set as the sum of all acceptable words produced in a one minute trial. In the abridged 
version (S-task) of the Controlled Oral Word Association Test [87], the subjects were 
required to generate as many words as possible beginning with the letter S within 60 
seconds [88]. 
Kendrick Object Learning Test 
The Kendrick Object Learning Test (KOLT) is commonly used in Norway and is 
designed to assess dementia status and memory performance among non-
institutionalized elderly [89]. The KOLT has been validated for the detection of 
memory impairment in old age [90]. Four cards with 10, 15, 20 and 25 pictures are 
shown individually for 30, 45, 60 and 75 seconds. When each card is taken away, the 
subject is asked to name as many pictures on the card as he or she can remember. A 
possible maximum KOLT score is 70. A score of 20 or less is categorized as severely 
memory impaired or demented, whereas a score of 21 to 25 is considered moderately 
memory impaired. The KOLT is of great value to community studies because it is 
normally distributed, and thus does not show a ceiling effect [91]. 
The Digit Symbol Test 
The digit symbol test consists of four rows containing in all 100 small blank squares, 
each paired with a randomly assigned number from one to nine. Above these rows is a 
printed key that pairs each number with a different nonsense symbol. Following a 
practice trial on the first ten or seven squares, the task is to fill in the blank spaces with 
the symbol that is paired to the number above the blank space as quickly as possible for 
90 seconds. The score is the number of squares filled in correctly. For most adults 
Digit Symbol is a test of psychomotor performance that is relatively unaffected by 
intellectual prowess, memory, or learning [86]. The modified version of the Digit 
Symbol Test [92] is regarded as a measure of focused attention, visuomotor 
coordination, and psychomotor speed. In the present version, the number of correct 
matches between digits and symbols in 30 seconds was recorded [88].  
Mini-Mental State Examination 
The Mini-Mental State Examination (MMSE) covers various aspects of cognitive 
function, including orientation to time and place, naming, repeating, writing, copying, 
instantaneous recall, short-term memory, backward spelling, and performing a 3-stage 
command [93]. This formalized mental status examination is probably the most widely 
used brief screening instrument for dementia used either alone or as a component in a 
test battery. It tests a restricted set of cognitive functions. Administration takes from 
five to ten minutes. The standardized administration and scoring procedures are easily 
learned. Scores below 24 are considered abnormal for dementia and delirium 
screening, but higher cut-off scores have been recommended for specific conditions. 
The modified version of the Mini Mental State Examination (m-MMSE) consists of 12 
of the 20 items in the full version of the MMSE and has been shown to be just as 
effective as the full version when the purpose is to identify elderly subjects with 
cognitive impairment [94]. 
Trail Making Test 
The trail making test is originally given in two parts, A and B. The subject must first 
draw lines to connect consecutively numbered circles on a work-sheet (Part A) and 
then connect the same number consecutively numbered and lettered circles on another 
worksheet by alternating between the two sequences (Part B). The subject is urged to 
connect the circles as fast as he/she can without lifting the pencil from the paper [86]. 
Reitan introduced the scoring method used in this study and is the most common one 
today [95]. The Trail Making Test, part A (TMT-A) is a test of visual conceptual and 
visuomotor tracking, involving motor speed and attention functions. The score is the 
total time in seconds to complete the items [88].  
Block Design 
The Block Design tests visuospatial and motor skills [86]. The Block Design test is a 
construction test in which the subject is presented with red and white blocks, four or 
nine, depending on the item. Each block has two white and two red sides, and two half-
red half-white sides with the colours divided along the diagonal. The task is to use the 
blocks to construct replicas of two block constructions made by the examiner and eight 
designs printed in smaller scale. The order of presentation differs in the order of 
difficulty. Generally, at each level of complexity, the even-numbered items are likely 
to be more difficult than the odd-numbered items. The short form (m-BD), used in the 
present study, included 4 of the 10 patterns presented in the original test (patterns 1, 2, 
5, and 6). Every correct matching gives 4 points; thus, a possible maximum score on 
the m-BD short form is 16 [88]. The test is normally discontinued after three failures. 
Block Design lends itself well to qualitative evaluation. The manner in which patients 
work at Block Design can reveal a great deal about their thinking processes, work 
habits, temperament, and attitudes toward themselves [86]. 
3.2.3 Other variables 
Serum concentrations of lipid-related factors, glucose and creatinine were measured at 
Ullevål hospital (Department of Clinical Chemistry) using a Hitachi 911 analyzer for 
the whole study. This analyzer comes with adapted reagents and measure methods 
from the company Boehringer Mannheim FRG (now: Roche, Basel, Switzerland). See 
also article in Norsk Epidemiologi 2003;13(1):85-88 (Norwegian): 
http://www.ub.ntnu.no/journals/norepid/2003-1/2003(1)Foss.pdf 
Nonfasting EDTA blood samples were collected for the measurement of total 
homocysteine (tHcy), creatinine and gene polymorphisms. The EDTA sample was kept 
cool until centrifuged. The blood samples were stored at -80 degrees C. The duration 
of storage ranged from a few days to 18 months. Plasma tHcy was measured by using a 
fully-automated HPLC assay [96, 97]. Apolipoprotein E (ApoE) genotypes were 
determined in the packed cell fraction of blood samples by using a one-stage 
polymerase chain reaction method [98].  
A history of cardiovascular disease (CVD) was defined as self-reported information at 
baseline, or during follow-up from 1992-1998. On the basis of information from both 
surveys, the subjects were categorized as with or without a history of CVD (myocardial 
infarction, angina pectoris, stroke, thrombosis, phlebitis, and hypertension). A history 
of diabetes was self-reported [88].  
Educational level was self-reported and recorded in 6 categories: Not completed 
primary school, primary school (9 years), technical college (10-12 years), secondary 
school (10-12 years), and college or university less than 4 years and more than four 
years. 
The follow-up study in 1997-99 included assessment of anxiety and depression using 
the Hospital Anxiety and Depression Scale (HADS) which consists of two 7-item 
subscales, HADS-A for anxiety and HADS-D for depression [99, 100]. HADS-A 
contains items mainly related to restlessness and worry, and one item reflects panic 
attacks. HADS-D focuses mainly on the reduced pleasure response aspect (anhedonia) 
of depression, but it also includes psychomotor retardation and impaired mood. In this 
study, only the HADS-D score was used as it is more relevant to cognitive function 
[101]. When tested, HADS-A was not associated with vitamin D. 
The smoking variable is coded as number of cigarettes smoked per day. 
Blood pressure was measured three times and the variable used in this study is the 
average of the second and third measurements. 
3.3 Statistical Analyses 
All calculations were performed by using SPSS 16.0 (SPSS INC, Chicago IL). Results 
are expressed as medians with 25th and 75th percentiles or means with standard 
deviations (SD). Pearson’s chi-square test and Student’s t-test were used to examine 
relationships between independent groups. Univariate ANOVA was used to compare 
the effectiveness of taking cod liver oil on total vitamin D intake. Spearman’s rho 
correlation coefficients were used to assess simple correlations. Multiple linear and 
logistic regression analyses were performed to examine relationships between intake of 
vitamin D (entered as quintiles) and the cognitive test scores adjusted for relevant 
covariates.  In the logistic regression analyses, the categories of intake were chosen to 
examine whether a low intake would increase the risk of scoring poorly on a cognitive 
test using the highest quintile as reference (vitamin D intake ≥15.7µg/d). A poor 
cognitive test score was set to the ~10th percentile for all the tests, except for the TMT-
A, where the 90th percentile was used [88, 102]. To avoid over-adjustment, three 
regression models were routinely used; first adjusting for sex only, then two with 
multiple adjustments. When adjusting for potential confounders, it was decided to 
adjust only for well established determinants of cognitive function (e.g. education, 
ApoE variant ε4 allele status) or for variables that were significantly associated with 4 
or more of the cognitive tests (including sum Z-score) as well as vitamin D intake. In 
the second model, the following variables were included: sex (men or women), 
education (6 categories), ApoE ε4variant allele (presence or not presence of ε4 variant 
allele), tHcy (quintiles), and total energy intake (quintiles). The third model also 
included nutritional covariates (quintiles) in addition to the aforementioned variables. 
Consequently, this model adjusted for sex, ApoE variant ε4 allele, education, tHcy, 
total energy intake, cereals, meat and meat products, fruit, vegetables, sweets, tea and 
wine. Month of cognitive testing in relation to the cognitive scores was assessed. For 
several of the tests, the lowest scores obtained were in August and September. 
However, adjusting for this variable did not change the results and it has been omitted 
from the final analyses. 
Because the subjects in this sub-study are homogenous in age, age is not included as a 
cofactor in the statistical models. 
It was chosen to enter continuous adjustment variables as quintiles in the regression 
models. Thus, log-transformation and the use of geometric means could be avoided. 
Cod liver oil is an important source of vitamin D in the present population. 
Multivariate linear regression analysis was used to investigate whether intake of cod 
liver oil was associated with KOLT score. Three regression models were used, where 
the two first models were as previously described. The third model adjusted for other 
vitamin D containing sources in addition to the variables in model 2. The third model 
therefore included sex, ApoE variant ε4 allele, education, tHcy, total energy intake, 
fatty fish, lean fish, fish remaining, butter/margarines, dairy products, eggs and other 
kinds of supplements. Again, all continuous variables were entered as quintiles. 
Binary logistic regression analysis was performed to examine if intake of lean fish and 
fatty fish affected the risk of scoring poorly on the KOLT differently in users/non-
users of cod liver oil. KOLT score was entered as dependent variable (dichotomous, 
10th percentile as cut-off) and intake of lean fish (4 categories: 0, 0.1 – 25.0, 25.1 – 
50.0 and ≥50.1 g/d) and fatty fish (4 categories: 0.0, 0.1 – 10.0, 10.1 – 20.0 and ≥20.1 
g/d) was entered as indicator variables. For both types of fish the highest intake group 
was used as reference. In addition to adjust for lean fish and fatty fish mutually, we 
also adjusted for sex, education, ApoE ε4 variant allele, tHcy and total energy intake. 
Also, a model was created that adjusted for other important sources of vitamin D 
(butter/margarine and other types of fish, dairy products, eggs and the remaining 
supplements, in quintiles). Finally, the same analysis was also conducted by entering 
cod liver oil as an adjustment variable instead of selection variable (3 categories: 0, 0.1 
– 2.5, ≥2.6 g/d). 
The distributions of the different tests varied greatly, and whereas the S-task, KOLT, 
m-DST and Z-scores were more or less normally distributed, the distributions of the m-
MMSE, TMT-A and m-BD were markedly skewed (Fig 2). The tests differ in nature, 
and the m-MMSE, TMT-A have a ceiling effect. In addition, the TMT-A has a rather 
untraditional appearance. The histogram (Fig 2) suggests that it is a clear divide within 
the population. We have not been able to map out what could be the reason for such a 
pattern, but have speculated that there is a discrepancy perhaps in the execution of the 
test. Even though some of the data were not normally distributed, it was chosen to 
analyse them using linear regression analyses as the sample size is very large [103]. 
For some of these tests, logistic regression analyses obviously appear to be more 
appropriate. 
All P-values are 2-sided, and values < 0.05 were considered significant. 
Fig 2. Histograms showing the distributions of the different cognitive tests 
  
  
 
  
 
 
 
 
 
4. Results 
4.1 Dietary intake 
The intake of vitamin D in the present population ranged from 0.5 to 56.1 µg/d. The 
distribution of vitamin D intake in the total population is depicted in Figure 3.  
Figure 3. Distribution of Vitamin D intake in the total population 
 
 
In the total population, intake of fish and fish products was the most important food 
group with fatty fish as the source that provided the most vitamin D (Table 4). 
Butter/margarines were the second most important source of vitamin D, followed by 
supplement use. Within the supplement category, cod liver oil was the strongest 
provider of vitamin D. Eggs and dairy products have small amounts of vitamin D in 
them and contributed modestly to the total intake of vitamin D. 
Table 4. Sources of vitamin D, the mean contribution of each source, and intake 
of the food group in the total population 
Total population (n = 1916) 
  Mean1 Median2  Contribution3 
Supplements total    
Total intake (g/d) 2.1 (3.5) 0.0 (0.0, 2.8)  
Vitamin D (µg/d) 4.2 (7.1) 0.0 (0.0, 6.05) 23.4 (31.3) 
Cod liver oil    
Total intake (g/d) 1.7 (3.0) 0.0 (0.0, 2.0)  
Vitamin D (µg/d) 3.6 (6.5) 0.0 (0.0, 4.3) 18.8 (29.1) 
Supplements remaining    
Total intake (g/d) 0.4 (1.6) 0.0 (0.0, 0.0)  
Vitamin D (µg/d) 0.6 (2.1) 0.0 (0.0, 0.0) 4.6 (13.9) 
Fish total    
Food intake (g/d) 88.6 (55.5) 80.3 (49.6, 116)  
Vitamin D (µg/d) 3.4 (3.2) 2.5 (1.1, 4.6) 38.3 (24.4) 
Fish fatty    
Food intake (g/d) 14.7 (16.9) 9.3 (2.4, 20.9)  
Vitamin D (µg/d) 2.1 (2.4) 1.3 (0.4, 3.1) 22.8 (20.9) 
Fish lean    
Food intake (g/d) 36.6 (29.4) 29.7 (15.0, 50.5)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3) 3.2 (3.6) 
Fish remaining    
Food intake (g/d) 37.7 (29.2) 32.4 (18.3, 49.2)  
Vitamin D (µg/d) 1.1 (1.4) 0.7 (0.1, 1.5) 12.3 (13.2) 
Butter    
Food intake (g/d) 26.1 (17.3) 23.4 (13.1, 35.3)  
Vitamin D (µg/d) 2.0 (1.2) 1.8 (1.1, 2.7) 31.5 (22.0) 
Eggs    
Food intake (g/d) 15.8 (11.5) 15.3 (7.7, 19.4)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3) 3.9 (5.0) 
Dairy products    
Food intake (g/d) 343 (206) 321 (195, 458)  
Vitamin D (µg/d) 0.1 (0.1) 0.1(0.1, 0.2) 2.4 (7.1) 
1 Mean (SD)    
2 Median with 25th and 75th percentiles  
3 Mean % contribution (SD)   
 
When dividing the population into users and non-users of cod liver oil, the pattern of 
contribution from the different food items changed (Table 5). For those that took cod 
liver oil, it was by far the main contributor of vitamin D. In the non-user group fish and 
fish products as well as butter/margarines were important sources of vitamin D. Eggs 
and dairy products also contributed more in the non-user group of cod liver oil.  
 
Table 5. Sources and their mean contribution of vitamin D divided into users and non-users of cod liver oil 
  User (n = 710) Non-user (n = 1206) 
  Mean1 Median2 Contribution3 Mean Median Contribution 
Vitamin D total 16.7 (8.9) 15.5 (10.1, 23.9)  6.0 (4.1) 5.2 (3.1, 7.8)  
Supplements total   55.7 (24.8)   4.4 (14.7) 
Food intake (g/d) 5.0 (4.1) 5.1 (1.7, 6.5)  0.3 (1.4) 0.0 (0.0, 0.0)  
Vitamin D (µg/d) 10.6 (8.1) 11.0 (4.1, 15.1)  0.4 (1.6) 0.0 (0.0, 0.0)  
Cod liver oil   50.8 (25.7)   0 
Food intake (g/d) 4.5 (3.5) 5.1 (1.4, 5.6)  0.0 (0.0) 0.0 (0.0, 0.0)  
Vitamin D (µg/d) 9.7 (7.5) 11.0 (3.0, 12.1)  0.0 (0.0) 0.0 (0.0, 0.0)  
Supplements rest   4.9 (12.3)   4.4 (14.7) 
Food intake (g/d) 0.5 (1.9) 0.0 (0.0, 0.0)  0.3 (1.4) 0.0 (0.0, 0.0)  
Vitamin D (µg/d) 0.9 (2.6) 0.0 (0.0, 0.0)  0.4 (1.6) 0.0 (0.0, 0.0)  
Fish total    24.7 (18.3)   46.4 (24.0) 
Food intake (g/d) 98.7 (58.3) 90.6 (59.2, 125)  83.2 (52.9) 74.9 (44.9, 111)  
Vitamin D (µg/d) 3.8 (3.3) 2.9 (1.4, 5.2)  3.1 (3.1) 2.3 (1.0, 4.2)  
Fatty fish   14.9 (14.3)   27.4 (22.7) 
Food intake (g/d) 16.6 (16.9) 11.3 (3.5, 24.0)  13.6 (16.7) 8.2 (2.1, 19.4)  
Vitamin D (µg/d) 2.4 (2.4) 1.6 (0.5, 3.4)  1.9 (2.4) 1.2 (0.3, 2.8)  
Lean fish   1.8 (1.8)   4.1 (4.08) 
Food intake (g/d) 40.3 (32.0) 34.1 (17.8, 53.8)  34.4 (27.5) 27.5 (15.0, 48.9)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3)  0.2 (0.2) 0.2 (0.1, 0.3)  
Fish rest   8.0 (8.9)   14.9 (14.6) 
Food intake (g/d) 41.9 (31.1) 36.5 (23.0, 52.9)  35.2 (27.7) 30.3 (16.0, 46.9)  
Vitamin D (µg/d) 1.2 (1.6) 0.8 (0.2, 1.7)  1.0 (1.4) 0.5 (0.1, 1.4)  
Butter/margarines   16.6 (13.2)   40.3 (21.4) 
Food intake (g/d) 63.9 (37.8) 57.9 (36.0, 81.8)  55.9 (37.5) 48.1 (28.4, 75.2)  
Vitamin D (µg/d) 1.8 (1.2) 1.6 (0.8, 2.5)  1.7 (1.1) 1.5 (0.9, 2.4)  
Eggs   1.7 (1.7)   5.3 (5.7) 
Food intake (g/d) 15.4 (10.8) 15.4 (7.7, 19.4)  16.0 (11.9) 15.3 (7.7, 19.4)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3)  0.2 (0.2) 0.2 (0.1, 0.3)  
Dairy products   1.1 (1.1)   3.2 (3.5) 
Food intake (g/d) 367 (208) 346 (217, 485)  328 (203) 301 (180, 435)  
Vitamin D (µg/d) 0.1 (0.1) 0.1 (0.1, 0.2)   0.1 (0.1) 0.1 (0.1, 0.1)   
1 Mean (SD) all such values      
2 Median (25th and 75th percentiles) all such values     
3 Mean % contribution (SD) all such values    
Figure 4 shows the distribution of vitamin D intake when the population is divided in users 
and non-users of cod liver oil. More people had a higher intake of vitamin D in the user-
group. 
Figure 4. Distribution of vitamin D intake in users and non-users of cod liver oil 
  
 
Cod liver oil was an important source of vitamin D in this population. Table 6 shows that of 
those that took cod liver oil as a supplement, 76.1% reached the recommended intake of 
vitamin D, whereas only 12.4% of the non-users reached the recommended intake level. A 
significantly larger portion of the users reached the recommended intake levels of vitamin D 
compared to the non-users (X2 test, P<0.001). 
Table 6. Number of users and non-users of cod liver oil according to the Nordic 
recommendations of vitamin D intake 
  Vitamin D intake 
    Total Low (<10 µg/d) Adequate (≥10 µg/d) % 
Cod liver oil User 710 170 540 76.1 
 Non-user 1206 1056 150 12.4 
  Total 1916 1226 690   
 
Univariate ANOVA adjusted for sex, ApoE e4 variant allele, education, tHcy and total 
energy intake showed a significantly higher intake of total vitamin D in the users of cod liver 
oil compared to the non-users (Table 7). 
Table 7. Vitamin D intake classified by the use of cod liver oil 
 CLO  
 User Non-user  
  n Mean 95% CI n Mean 95% CI P-value1  
Vitamin D intake 672 16.5 16.0, 16.9 1089 6.5 6.1, 6.8 <0.001 
1 ANOVA adjusted for sex ApoE e4 variant allele, education, tHcy and total energy intake 
 
4.2 Cognitive performance 
Upon defining a low cognitive test score as the tenth percentile (90th for the TMT-A) only 3 
subjects were defined as scoring poorly on all of the cognitive tests. Table 8 summarises the 
results from the cognitive testing. Z-scores are also included. The number of participants 
defined as scoring poorly on the different test varied. The number of people that scored 
poorly on at least one test was 678 comprising of 35.4% of the participants. 
Table 8. Cognitive performance in the total population 
Total population (n = 1916) 
  Mean1 Median2 Lowest Highest Cut-off3 %4 
S-task 15.3 (5.5) 15.0 (12.0, 19.0) 1 39 ≤ 8 (184) 9.6 
KOLT 35.4 (8.0) 35.0 (30.0, 41.0) 2 65 ≤ 25 (180) 9.4 
m-DST 10.4 (4.2) 9.0 (7.0, 13.0) 1 24 ≤ 6 (154) 8.0 
m-MMSE 11.6 (0.7) 12.0 (11.0, 12.0) 5 12 ≤ 10 (155) 8.1 
TMT-A 55.5 (32.5) 44.0 (36.0, 55.0) 16 248 ≥ 109 (192) 10.0 
m-BD 15.1 (2.2) 16.0 (16.0, 16.0) 1 16 ≤ 12 (265) 13.8 
Z-score 0.0 (1.0) 0.1 (-0.5, 0.7) -5.0 2.7 ≤ -1.3 (191) 10.0 
1 Mean (SD)     
2 Median (25th and 75th percentiles)     
3 Cut-off point for scoring poorly (number of subjects below that cut-off)  
4 Percent of the population defined as scoring poorly on the test   
4.3 Adequate vs. low intake of vitamin D 
In accordance with the Nordic recommendations, an intake of  ≥10 µg/d was considered an 
adequate intake for this age group [18]. Sixty-four percent of the population did not meet the 
Nordic recommendations of vitamin D intake. More men than women were significantly 
classified as having an adequate intake of vitamin D (Table 9). The educational level as well 
as total energy intake was significantly higher in the adequate intake group compared to the 
low intake group. In an attempt to map out what could be the reason for the skewness in 
energy intake between the two vitamin D intake categories, we tested if the plasma variables 
for tHcy, vitamin B12, folate, methylmalonic acid and creatinine were different between the 
adequate intake group and low intake group. tHcy was the only variable that differed 
between the two intake groups and was significantly higher in the low intake group (P = 
0.027). 
Four of the cognitive tests were significantly higher in the adequate intake group compared 
to the low intake group (S-task, m-DST, m-MMSE and Z-score). Plasma tHcy was 
significantly higher in the low intake group. There was no significant difference in ApoE ε4 
variant allele profile, smoking status, blood pressure, BMI, CVD or diabetes history when 
comparing the two intake groups. Plasma creatinine was borderline significantly higher in 
the adequate intake group. 
 
Table 9. Adequate vs. low intake of vitamin D 
  Adequate (≥10 µg)  Low (<10 µg)  
  n n (%) or mean (SD) n n (%) or mean (SD) P value1 
Sex (male) 690 393 (57.0) 1226 490 (40.0) <0.001 
Education ≤9 y 651 205 (31.5) 1128 460 (40.8) <0.001 
Daily smoker (yes) 690 91 (13.2) 1225 156 (12.7) 0.866 
Number of cigarettes/d amongst smokers 91 9.5 (4.5) 156 10.6 (7.9) 0.638 
BMI 690 25.9 (3.7) 1223 26.2 (4.0) 0.182 
Total energy (kJ) 690 8671 (2272) 1226 6964 (2062) <0.001 
Vitamin D (µg/d) 690 18.8 (7.6) 1226 5.1 (2.4) <0.001 
      
      
Systolic blood pressure 690 146 (21) 1226 146 (20) 0.928 
Diastolic blood pressure 690 78 (12) 1226 77 (12) 0.160 
History of CVD (yes) 677 216 (31.9) 1192 411 (34.5) 0.279 
Diabetes (yes) 678 39 (5.8) 1211 85 (7.5) 0.332 
Depression score 664 3.3 (2.7) 1129 3.6 (2.8) 0.085 
      
Cognitive test scores      
S-task 690 15.0 (5.3) 1226 15.8 (5.7) 0.001 
KOLT 690 35.2 (8.2) 1226 35.8 (7.6) 0.097 
m-DST 690 10.2 (4.2) 1226 10.8 (4.3) 0.002 
m-MMSE 690 11.5 (0.8) 1226 11.6 (0.7) 0.047 
TMT-A 690 57 (33) 1226 54 (32) 0.074 
m-BD 690 15.1 (2.2) 1226 15.1 (2.1) 0.692 
Z-score 690 0.96 (0.98) 1226 -0.05 (1.01) 0.002 
      
Plasma variables and ApoE status      
tHcy (µmol/L) 690 11.7 (3.6) 1221 12.1 (3.9) 0.027 
Creatinine (µmol/L) 690 78.3 (19.4) 1219 76.4 (18.6) 0.053 
ApoE (allele present) 686 214 (31.2) 1216 392 (32.2) 0.645 
1 Pearson X2-test corrected for continuity or Student’s t-test      
4.4 Unadjusted analyses including Student’s t-tests and simple 
correlations 
Men scored better on the TMT-A and women scored better on the KOLT (Table 10). None 
of the other cognitive tests differed according to sex. Intake of vitamin D was higher for 
men than for women. 
ApoE ε4 variant allele was associated with significantly lower test scores for KOLT, m-
MMSE, m-DST and Z-score. The S-task, the KOLT and Z-score were significantly poorer 
for those with a history of CVD. The S-task, KOLT, m-DST and Z-score were significantly 
higher for the subjects without diabetes. Vitamin D did not differ significantly when testing 
for either ApoE ε4 variant allele, history of CVD or diabetes (Table 10). 
 
 Table 10. Student’s t-test for dichotomous variables in relation to cognitive test scores and vitamin D intake 
  Sex ApoE ε4 variant allele CVD Diabetes 
  
Mean 
difference1 P value3 
Mean 
difference2 P value 
Mean 
difference2 P value 
Mean 
difference2 P value 
COWAT -0.04 0.862 -0.25 0.347 -0.57 0.035 -1.72 0.001 
KOLT -3.19 <0.001 -1.19 0.002 -1.67 <0.001 -1.66 0.024 
m-DST 0.15 0.44 -0.52 0.012 -0.21 0.323 -0.91 0.021 
m-MMSE 0.03 0.32 -0.1 0.011 -0.05 0.184 -0.1 0.132 
TMT-A -3.47 0.019 3.19 0.055 3.05 0.057 3.13 0.299 
m-BD 0.14 0.16 -0.03 0.776 -0.12 0.261 -0.2 0.327 
Z-score -0.06 0.171 -0.13 0.007 -0.16 0.001 -0.29 0.002 
Vitamin D 2.96 <0.001 0.25 0.529 -0.09 0.821 -0.53 0.493 
1 Men - women       
2 Sick - healthy        
3 P value from Student's t-test (all such values)     
 
Table 11 shows Spearman’s Rho correlation coefficients between continuous variables, the 
cognitive tests and vitamin D intake. Of the cognitive tests, vitamin D intake was correlated 
with S-task, m-DST, m-MMSE, TMT-A, and sum Z-score. Of the other variables vitamin D 
was associated with education, plasma tHcy, plasma creatinine, total energy intake and all of 
the food groups. At least four of the cognitive tests including sum Z-score were associated 
with the following variables: education, intake of total energy, depression score, 
supplements, fish total (including all fish and fish products), lean fish, fatty fish, dairy 
products, fruit, meat and meat products, cereals, vegetables, sweets and drinks (tea and 
wine). Coffee was not associated with vitamin D intake. Among the nutritional variables, 
fruit, meat and meat products, cereals, vegetables, sweets and drinks did not contain vitamin 
D and were considered potential confounders. 
Table 11. Spearman’s Rho correlation coefficients for continuous variables, the cognitive tests and vitamin D intake 
  n S-task KOLT m-DST m-MMSE TMT-A m-BD Z-score Vitamin D 
Vitamin D 1916 0.12** 0.03 0.08** 0.05* -0.05* 0.04 0.10** 1.00 
Education 1779 0.33** 0.11** 0.42** 0.20** -0.27** 0.17** 0.40** 0.15** 
tHcy 1911 -0.06** -0.14** -0.06* -0.04 0.07** -0.02 -0.11** -0.05* 
BMI 1913 -0.05* -0.05* -0.03 -0.02 -0.02 -0.02 -0.05* -0.04 
Depression score 1793 -0.06* -0.10** -0.10** -0.01 0.10** -0.04 -0.12** -0.03 
Smoking 1916 0.00 -0.01 -0.03 -0.02 0.07** -0.07** -0.05* 0.03 
Creatinine 1909 0.03 -0.10** 0.01 0.03 -0.05* 0.05* 0.00 0.09* 
Systolic blood pressure 1916 -0.05* 0.01 -0.03 -0.05* 0.01 0.01 -0.03 -0.01 
Diastolic blood pressure 1916 -0.03 -0.02 -0.01 -0.00 -0.04 0.02 0.00 0.05* 
          
Total energy 1916 0.06* -0.03 0.06* 0.04 -0.01 0.05* 0.05* 0.48** 
          
Supplements 1916 0.12** 0.05* 0.07** 0.04 -0.05* 0.04 0.10** 0.75** 
Fish 1916 0.05* 0.05* 0.07** 0.07** -0.07** 0.07** 0.09** 0.53** 
Fatty 1916 0.06** 0.06** 0.06** 0.03 -0.06** 0.03 0.08** 0.50** 
Lean and medium 1916 0.02 0.06** 0.04 0.08** -0.05* 0.06* 0.07** 0.29** 
Butter/oils 1916 0.02 -0.05 0.06** 0.04 -0.04 0.07** 0.05* 0.35** 
Eggs 1916 -0.00 0.0.3 -0.05* 0.02 0.01 -0.02 -0.04 0.12** 
Dairy products 1916 -0.05* -0.02 -0.09** -0.02 0.08** 0.02 -0.07** 0.14** 
Fruit 1916 0.13** 0.12** 0.14** 0.08** -0.09** 0.10** 0.18** 0.23** 
Meat and meat products 1916 0.06** 0.01 0.07** 0.07** -0.03 0.07** 0.07** 0.31** 
Cereals 1916 0.07** 0.03 0.09** 0.05* -0.10** 0.11** 0.11** 0.22** 
Vegetables 1916 0.11** 0.09** 0.11** 0.11** -0.09** 0.05* 0.15** 0.25** 
Sweets 1916 0.09** 0.04 0.10** 0.02 -0.05* 0.07** 0.11** 0.15** 
Drinks          
Tea 1916 0.10** 0.09** 0.13** 0.09** -0.11** 0.05* 0.16** 0.06* 
Wine 1916 0.23** 0.14** 0.23** 0.15** -0.17** 0.09** 0.27** 0.16** 
Coffee 1916 -0.06** -0.03 -0.09** -0.03 0.08** -0.04 -0.10** 0.00 
* Significant at 0.05 level          
** Significant at 0.01 level          
4.5 Linear regression analyses 
Linear regression analyses adjusted for sex indicated that a significant association between 
quintiles of vitamin D intake as independent variable and the S-task, KOLT, m-DST, m-
MMSE or the sum Z-scores as dependent variable existed (Table 12). After additional 
adjustment with ApoE ε4 variant allele, education, tHcy, and energy intake, the S-task and 
KOLT remained significantly associated with intake of vitamin D (Table 12). The 
association was markedly reduced compared to the sex-adjusted model. Further 
investigation revealed that inclusion of education and total energy intake accounted for the 
weakening of this association. In the final model, including adjustment for nutrients and 
disease variables, none of the cognitive tests remained significant.  
Table 12. Linear regression analysis showing the relationship between vitamin D 
intake and the different cognitive tests 
  B SE Partial r P-value    
S-task 0.452 0.535 0.114 <0.001    
KOLT 0.433 0.129 0.077 0.001    
m-DST 0.244 0.070 0.079 0.001    
m-MMSE 0.028 0.012 0.052 0.022    
TMT-A -0.553 0.537 -0.02 0.304    
m-BD 0.064 0.036 0.04 0.075    
Z-scores 0.075 0.016 0.103 <0.001    
Adjusted for sex       
        
             
  B SE Partal r P-value    
S-task 0.227 0.099 0.055 0.021    
KOLT 0.304 0.149 0.049 0.041    
m-DST 0.007 0.076 0.00 0.930    
m-MMSE 0.006 0.014 0.01 0.649    
TMT-A 0.412 0.600 0.02 0.493    
m-BD -0.007 0.039 0.00 0.857    
Z-scores 0.020 0.017 0.03 0.246    
Adjusted for sex, ApoE ε4 variant allele, education, tHcy and total energy intake 
        
             
  B SE Partial r P-value    
S-task 0.176 0.098 0.043 0.074    
KOLT 0.229 0.148 0.037 0.122    
m-DST -0.025 0.076 -0.008 0.740    
m-MMSE 0.000 0.014 0.001 0.973    
TMT-A 0.689 0.598 0.028 0.250    
m-BD -0.017 0.040 -0.010 0.676    
Z-scores 0.008 0.017 0.011 0.637    
Adjusted for sex, ApoE ε4 variant allele, education, tHcy, total energy intake, cereals, 
meat and meat products, fruit, vegetables, sweets, tea and wine  
 
4.6 Risk of poor cognitive test performance according to 
vitamin D intake 
The risk of scoring poorly on a cognitive test according to quintiles of vitamin D intake was 
explored by the use of binomial logistic analysis. The upper quintile of vitamin D was used 
as the reference category. 
In the model adjusted only for sex, when comparing the highest and lowest quintiles of 
vitamin D intake, there was an increase in risk for scoring poorly on the KOLT, m-DST, m-
MMSE, and the sum Z-score (Table 13). In the second model, none of the P trends stay 
significant, but the increased risk of scoring poorly on the KOLT was significant at the 
lowest quintile of vitamin D intake. When introducing more covariates in the models, none 
of the tests remained significant (Table 13). 
Table 13. Binary logistic regression analyses 
    n OR1 95% CI   OR2 95% CI   OR3 95% CI 
S-task           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.84 0.51, 1.36  0.68 0.39, 1.16  0.67 0.39, 1.16 
 5.96 - 9.19 384 0.73 0.44, 1.22  0.74 0.43, 1.28  0.73 0.42, 1.26 
 3.58 - 5.95 384 1.08 0.67, 1.73  0.94 0.56, 1.59  0.89 0.52, 1.51 
 ≤ 3.57 382 1.40 0.88, 2.23  1.10 0.73, 2.29  1.12 0.66, 2.09 
P trend   0.095   0.318   0.540  
KOLT           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.87 0.54, 1.46  0.89 0.52, 1.48  0.92 0.54, 1.57 
 5.96 - 9.19 384 1.01 0.62, 1.67  1.00 0.59, 1.68  0.98 0.58, 1.66 
 3.58 - 5.95 384 0.94 0.57, 1.57  0.71 0.41, 1.26  0.68 0.38, 1.21 
 ≤ 3.57 382 1.74 1.08, 2.80  1.81 1.04, 3.15  1.65 0.94, 2.89 
P trend   0.033   0.161   0.331  
m-DST           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.86 0.46, 1.59  0.76 0.38, 1.50  0.75 0.38, 1.48 
 5.96 - 9.19 384 1.21 0.68, 2.14  1.31 0.70, 2.45  1.28 068, 2.40 
 3.58 - 5.95 384 1.78 1.04, 3.04  1.27 0.68, 2.37  1.21 0.65, 2.27 
 ≤ 3.57 382 1.90 1.11, 3.26  1.55 0.79, 3.05  1.43 0.72, 2.83 
P trend   0.001   0.092   0.156  
m-MMSE           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.54 0.30, 1.00  0.39 0.19, 0.79  0.41 0.20, 0.83 
 5.96 - 9.19 384 1.04 0.61, 1.75  0.95 0.54, 1.67  0.92 0.52, 1.63 
 3.58 - 5.95 384 1.26 0.76, 2.10  0.94 0.54, 1.66  0.91 0.52, 1.61 
 ≤ 3.57 382 1.40 0.84, 2.32  0.88 0.47, 1.64  0.83 0.44, 1.55 
P trend   0.018   0.609   0.817  
TMT-A           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.96 0.58, 1.57  0.79 0.46, 1.36  0.84 0.48, 1.45 
 5.96 - 9.19 384 1.18 0.73, 1.89  1.20 0.73, 2.00  1.26 0.76, 2.11 
 3.58 - 5.95 384 1.16 0.72, 1.86  0.91 0.53, 1.54  0.89 0.52, 1.51 
 ≤ 3.57 382 1.10 0.62, 1.66  0.78 0.43, 1.41  0.69 0.38, 1.26 
P trend   0.690   0.636   0.368  
m-BD           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 0.99 0.65, 1.50  0.83 0.53, 1.31  0.84 0.53, 1.33 
 5.96 - 9.19 384 0.83 0.54, 1.28  0.80 0.50, 1.26  0.80 0.51, 1.28 
 3.58 - 5.95 384 1.02 0.67, 1.54  0.74 0.46, 1.17  0.72 0.45, 1.15 
 ≤ 3.57 382 1.30 0.87, 1.95  0.94 0.58, 1.53  0.86 0.53, 1.42 
P trend   0.215   0.605   0.404  
Z-scores           
 ≥ 15.63 382 ref   ref   ref  
 9.20 - 15.62 384 1.10 0.66, 1.85  0.96 0.55, 1.67  0.97 0.55, 1.71 
 5.96 - 9.19 384 1.25 0.76, 2.08  1.19 0.69, 2.05  1.18 0.68, 2.05 
 3.58 - 5.95 384 1.45 0.88, 2.37  0.94 0.53, 1.65  0.88 0.50, 1.55 
 ≤ 3.57 382 1.74 1.07, 2.83  1.31 0.72, 2.37  1.11 0.61, 2.02 
P trend     0.013     0.477     0.931   
1 Adjusted for sex          
2 Adjusted for sex, ApoE ε4 variant allele, education, tHcy and total energy intake  
3 Adjusted for sex, ApoE ε4 variant allele, education, tHcy, total energy intake, fruit, vegetables, meat and 
meat products, cereals, sweets, tea and wine 
4.7 Intake of Cod liver oil, lean fish and fatty fish in relation to 
scoring poorly on an episodic memory test (KOLT) 
Both fatty fish and cod liver oil were important sources of vitamin D (Table 4). There have 
previously been demonstrated a relationship between lean fish and KOLT score in this 
population [88]. Furthermore, the KOLT was the only test that was significantly associated 
with vitamin D intake in both linear and logistic regression analyses. The relationship 
between intakes of cod liver oil, lean fish, fatty fish and KOLT score were therefore further 
explored. 
The mean intakes of vitamin D, lean fish, fatty fish and fish total, fish remaining, dairy 
products and butter/margarines were all significantly higher in the user group of cod liver oil 
(Student’s t-test, all P-values < 0.001).  
In multivariate linear regression analysis when adjusting for sex, both fatty fish intake and 
lean fish intake were significantly associated with KOLT score. Intake of cod liver oil was 
not significantly associated (Table 14). When further adjusting for ApoE ε4 variant allele, 
education, tHcy and total energy, the association between intake of cod liver oil and KOLT 
score was weakened. The association between both fatty fish intake and lean fish intake in 
relation to KOLT score was only moderately reduced (Table 14). In the fully adjusted 
model, when further adjusting for other vitamin D containing food sources 
(butter/margarines, fish remaining, supplements remaining, eggs and dairy products) and 
keeping fatty fish and lean fish in the model, the association between cod liver oil and 
KOLT score was further weakened. The association between intakes of fatty fish and lean 
fish and KOLT score was still significantly associated and only slightly weakened (Table 
14). 
Table 14. Linear regression analyses exploring the relationship between intakes of cod 
liver oil, fatty fish, lean fish and KOLT score 
Modell 11    
  B SE partial P value    
Cod liver oil 0.234 0.141 0.038 0.099    
Fish fatty 0.527 0.127 0.094 <0.001    
Fish lean 0.660 0.129 0.116 <0.001    
             
Modell 22    
  B SE partial P value    
Cod liver oil 0.085 0.147 0.014 0.563    
Fish fatty 0.498 0.135 0.087 <0.001    
Fish lean 0.540 0.138 0.093 <0.001    
             
Modell 33    
  B SE partial P value    
Cod liver oil 0.043 0.147 0.007 0.769    
Fish fatty 0.375 0.141 0.064 0.008    
Fish lean 0.436 0.142 0.073 0.002    
1 Adjusted for sex        
2 Adjusted for sex, ApoE e4 variant allele, education, tHcy and total energy intake 
3 Adjusted for sex, ApoE e4 variant allele, education, tHcy, total energy intake,    
butter/margarines, fish remaining, supplements remaining, eggs and dairy products 
 
For the non-users of cod liver oil, the risk of scoring poorly on the KOLT increased when 
the intake of lean fish was low (0.1 – 25.0 g/d, P = 0.027) (Table 15). No significant 
relationship was found when the same analysis was performed with fatty fish as indicator 
variable. 
Table 15. Logistic regression analyses exploring the relationship between intakes of 
lean fish and fatty fish, in users and non-users of cod liver oil, in regards to scoring 
poorly on the KOLT. 
   User (n = 672)  Non-user (n = 1089) 
    n OR 95% CI n OR 95% CI 
KOLT        
Lean Fish1 ≥ 50.1 g/d 198 ref  270 ref  
 25.1 - 50.0 g/d 242 0.76 0.36, 1.60 385 0.98 0.55, 1.74 
 0.1 - 25.0 g/d 194 1.23 0.57, 2.63 345 1.92 1.08, 3.43 
 0.0 g/d 38 0.71 0.15, 3.44 89 1.82 0.83, 3.99 
P trend   0.845   0.016  
        
Fatty Fish2 ≥ 20.1 g/d 204 ref  266 ref  
 10.1 - 20.0 g/d 165 0.74 0.77, 3.95 235 0.74 0.40, 1.38 
 0.1 - 10.0 g/d 216 1.47 0.64, 3.38 368 0.90 0.52, 1.57 
 0.0 g/d 87 1.87 0.69, 5.04 220 1.06 0.58, 1.69 
P trend     0.255     0.743   
1 Adjusted for sex, ApoE ε4 variant allele , education, tHcy, total energy and fatty fish 
2 Adjusted for sex, ApoE ε4 variant allele, education, tHcy, total energy and lean fish 
 
When further adjusting for other sources of vitamin D (butter/margarines, supplements 
remaining, fish remaining, eggs, and dairy products), the model weakened, but the same 
intake category for lean fish (0.1 – 25.0 g/d) remained significant (Table 15) in non-users of 
cod liver oil.  
Table 16. Logistic regression analyses exploring the relationship between intake of lean 
fish and fatty fish in users and non-users of cod liver oil in regards to scoring poorly on 
the KOLT. Multiple adjustments 
   User (n = 672)  Non-user (n = 1089) 
    n OR 95% CI n OR 95% CI 
KOLT        
Lean Fish1 ≥ 50.1 g/d 198 ref  270 ref  
 25.1 - 50.0 g/d 242 0.74 0.35, 1.57 385 0.96 0.53, 1.71 
 0.1 - 25.0 g/d 194 1.17 0.54, 2.54 345 1.81 1.00, 3.26 
 0.0 g/d 38 0.69 0.14, 3.44 89 1.72 0.78, 3.80 
P trend   0.933   0.031  
        
Fatty Fish2 ≥ 20.1 g/d 204 ref  266 ref  
 10.1 - 20.0 g/d 165 1.95 0.84, 4.51 235 0.71 0.39, 1.34 
 0.1 - 10.0 g/d 216 1.52 0.65, 3.58 368 0.85 0.48, 1.49 
 0.0 g/d 87 1.81 0.65, 5.03 220 1.00 0.54, 1.84 
P trend     0.296     0.886   
1 Adjusted for sex, ApoE ε4 variant allele, education, tHcy, total energy, fatty fish, butter/margarines, 
fish remaining, supplements remaining, eggs and dairy products. 
2 Adjusted for sex, ApoE ε4 variant allele, education, tHcy, total energy, lean fish, butter/margarines, 
fish remaining, supplements remaining, eggs and dairy products. 
 
When not using users/non-users of cod liver oil as a selection variable, but instead including 
intake of cod liver oil as an adjustment variable, and still using lean fish as an indicator 
variable, the increased risk of scoring poorly on the KOLT, when adjusting for sex, ApoE ε4 
variant allele, education, tHcy, total energy, fatty fish and other sources of vitamin D, was 
still almost significant for reduced lean fish intake (0.1 – 25.0 g/d, OR = 1.59, 95% CI: 0.98, 
2.47, P = 0.059).
5. Discussion 
5.1 Methodological considerations 
The validity of a study is often discussed in terms of internal and external validity. Internal 
validity implies the degree to which the estimated effect or association between exposure 
and outcome is true or valid for the source of the study [104]. In evaluating internal validity 
one needs to consider the likelihood that alternative explanations such as bias or 
confounding could account for the findings. External validity refers to generalisation of the 
study results [104]. 
5.1.1 Study design 
Observational studies are used to study factors or exposures that cannot be controlled by the 
investigator [105]. There are different types of observational studies, and the cross-sectional 
design is one of them. In a cross-sectional study, all the information is collected at the same 
time. The particular difficulty associated with cross-sectional studies when looking at 
associations with disease concerns the sequence in time of the disorder of interest and the 
possible risk factor. Because the data is collected at the same time it is not possible to draw a 
clear inference of causality [105].  
It is complicated to perform randomised controlled studies on cognitive decline. When a 
person start to show signs of cognitive impairment or dementia, intervention is already too 
late as the subject might have already changed his/her habits as a result of the disease. It 
becomes a near impossible task to conclude whether the person’s habits are a result of the 
disease or if the disease has developed secondary to the individual’s habits. Because 
dementia is a progressive disease, the cross-sectional design of the present study serves as a 
substantial limitation. 
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5.1.2 Statistical aspects 
An association between an exposure and outcome, or lack of association might be the result 
of chance. Sample size is directly related to chance. The probability that the results are due 
to chance decreases as the sample size increases [104]. Our study is one of the larger cohorts 
on cognition among elderly. Furthermore, because of a large sample size, very small 
differences were detected as significant. Whether a small effect size is considered important 
depends on the context of measurements compared. In medical and nutritional research, 
small effect sizes usually reflected by small increases of risk are often considered clinically 
relevant [104]. The large sample size is considered a strength in the present study. 
5.1.3 Bias and confounding 
Recruitment bias 
Recruitment bias denotes errors that result from systematic differences in characteristics 
between those who participated in the study and those who did not [104].  
Apart from affecting the observed prevalence of a disorder, the choice of sample may have a 
strong effect on the observed relation with other factors. The validity of the extrapolation 
depends crucially on the representativeness of the sample. It is an innate weakness of most 
observational studies that the sample is not representative of the population [105]. 
Non-participation can pose as a problem in cross-sectional studies. Many studies have found 
that there are marked differences (demographic and health related) between those who do or 
do not respond to a questionnaire, with the non-responders usually being less healthy [105]. 
Socio-demographic analyses of drop-outs and attendees in the HUSK study at large have 
been performed in regards to income, education, employment and disability and social 
pensions; 
(http://www.uib.no/isf/husk/Vedlegg_dokumenter/FrafallsanalyseHUSK9799.pdf). It 
showed that non-participants had significantly more unfavourable lifestyle characteristics. 
An under-representation of individuals with adverse risk factors, such as lower education, 
may leave the results non-representative. 
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In the present study, because 71% of the study participants volunteered for cognitive testing, 
recruitment bias may have been an issue. Differences between those that attended and those 
that did not attend the cognitive sub-study have been reported elsewhere [91]. A 
significantly higher percentage of the non-participants showed presence of ApoE ε4 variant 
allele, less education, higher levels of tHcy and lower vitamin B12 in serum. Furthermore, a 
higher percentage of the non-participants had CVD/hypertension [91]. More information on 
the study population can be found on the internet: 
(www.uib.no/isf/husk/Vedlegg_dokumenter/Cognitive_Sub_study.pdf) 
Confounding 
Confounding implies that the estimated effect of the exposure is mixed together with the 
effect of another factor, and so distorts the observed exposure-outcome association [106]. 
Confounding, or conclusion/distortion of effects, is of concern in all observational studies, 
but in contrast to selection and recall bias, confounding can be adjusted for in the analyses. 
The management of possible confounding relies on proper measurements and analytical 
approaches as well as knowledge of biological mechanisms [105]. In principle, a confounder 
should be associated with both the exposure and the outcome to exert a confounding effect 
and a factor that represents a step in the causal pathway between exposure and outcome 
should not be treated as a confounder [105]. ApoE ε4 variant allele and education are 
considered strong potential confounders of cognitive decline with age [107, 108]. 
Furthermore, foods are not consumed individually, but as part of a diet; therefore, 
confounding by other food items is always an issue in studies utilising dietary assessments. 
In the statistical analyses, we included adjustments for several potential confounders, but 
residual confounding cannot be excluded. 
Sun light exposure 
Sun light exposure could possibly have a confounding effect on cognitive test score. It was 
however chosen to not adjust for this variable in the final analyses. UVB wavelengths that 
are optimal for vitamin D production in the skin differ according to altitude, latitude and 
weather conditions [109, 110]. Norwegian people commonly travel to the mountains during 
the winter months and typically during Easter holiday [111]. UVB radiation has been shown 
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to be stronger at higher altitudes leading to better conversion of pre-vitamin D in the skin 
[110]. Furthermore, we did not have information on the use of tanning beds, which have 
been shown to be highly effective when it comes to the endogenous production of vitamin D 
[112, 113]. Also, people in Norway typically exhibit sun-seeking behaviour as they travel a 
lot to sunnier parts of the world, and especially during the winter months [111]. In addition, 
people in the HUSK study come from the western part of Norway, and the weather in this 
part of the country tend to be cloudy and rainy even during the months of summer. One 
study found that the conversion of vitamin D was reduced with as much as 20% on a cloudy 
day compared to a sunny day in the same month [110]. In addition, people’s capacity to 
make vitamin D in the skin is individually different, and also often reduced in the elderly 
[114]. Although information of month of cognitive testing was available, the 
abovementioned uncertainties related to sun-light exposure, led to the decision of omitting 
this variable from the final analyses. Also, adjusting for this variable did not change the 
results. 
Energy intake 
According to the Nordic Recommendations the energy intake in this age group should be 
10600 kJ (PAL = 1.6) for men and 8500 kJ for women (PAL = 1.6) [18]. These reference 
values are used on the basis that these adults are generally healthy and not institutionalised. 
The population in the present study had an energy intake of approximately 2000 kJ fewer 
than what is recommended. This was a consistent finding in both genders.  
The total energy intake was significantly higher in the adequate intake group of vitamin D 
compared to the low intake group. In theory, if the energy intake is lower in the low-intake 
group of vitamin D, this would become apparent in the serum values of the different vitamin 
markers, as the intake of those vitamins would probably be lower as a result of lower energy 
intake. When testing for differences in serum values between the two vitamin D intake 
categories, only tHcy differed significantly, and were higher in the low intake group. One 
explanation for the skewness in energy intake might be that the low-intake group had a 
significantly larger proportion of women than men, and the women in this population do 
indeed have a significantly lower energy intake than the men (as would be expected). We 
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have no explanation for the apparent low intake of energy in this population, but total energy 
intake and gender were adjusted for in the analyses.  
Information bias 
Information bias arise when the information collected from the study participants regarding 
exposure or outcome is incorrect and thus leads to systematic error in the effect estimation 
[104]. Studies requiring recall of detailed dietary habits are prone to this problem, often 
referred to as recall bias [105].  
The FFQ used in the present thesis has been validated by several studies [81, 82, 115]. 
Validation studies include 14 day weighed records with the intakes calculated from the FFQ 
in a group of 38 elderly women [115], the correlation between self-reported dietary intake of 
fish and essential omega-3 fatty acids in plasma phospholipids among 579 men and women 
[81], and 14-day weighed records with the intakes calculated from the FFQ in a group of 
125 men [82]. These studies show that the questionnaire is suitable to be used as an 
assessment tool when it comes to the estimation of intake of a wide range of micronutrients. 
None of the previously mentioned validation studies have, however, used vitamin D as a 
biomarker. 
Dietary assessment is a field of research that has several pitfalls associated with it. 
Participants might forget what they eat, or report what they think is expected of them. An 
FFQ can merely give the information on how the individual perceives his/her diet. It can 
never be an objective type of measurement. FFQs do, however, allow for a large population 
sample as they are less time consuming and expensive than other methods for mapping out 
peoples dietary habits, such as 24 hour recall or the weighing of food.  
People suffering from dementia or other forms of cognitive impairments might have 
changed their diet as a result of the disease. Consequently, self-reported dietary data 
collected from people that are cognitively impaired or demented may be less reliable. 
However, because these were free-living subjects and the vast majority were not impaired, it 
seems unlikely that this would have a major impact on the findings. 
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Data on serum vitamin D levels were not available in the present population, and serves as a 
limitation in the study. However, methods for measuring vitamin D in serum are under 
scrutiny as they show large discrepancies between method variation [1]. An evaluation of 
seven methods using 291 EDTA plasma samples showed that all methods except HPLC 
demonstrated significant negative bias compared with the “gold standard” liquid 
chromatography-mass spectrometry [116]. Serum levels are an objective measure and it 
would have been of great value to have information on both dietary intake and serum levels.  
The cognitive tests used in this thesis have been well validated [95, 117-120]. These tests, 
although frequently used in the clinic, are however never the sole grounds for diagnosing 
someone with dementia [121]. Psychiatric evaluation as well as input from the close family 
of the individual are emphasised to a high degree. For research purposes though, the tests as 
screening instruments serve as valuable tools for the investigator. The size of the test battery 
in this study is of particular importance as it made it possible to investigate if some areas of 
cognition were more affected than others. 
5.1.4 Generalisation 
Generalisation, or external validity, refers to whether a study can produce inferences 
regarding a target population beyond the population sample of the study [104]. Because 
comparisons between those who were cognitively tested and those who were not revealed 
differences between the groups, it is unlikely that the study population is fully representative 
of the general elderly population. One should therefore be careful not to extrapolate the 
results. However, the strength of this study is the large sample size, its recruitment from the 
general population and the comprehensive cognitive test battery. Thus, even if the cognitive 
study population was modestly healthier and differed in certain characteristics from those 
that did not attend, we still believe that the subjects represent a relatively large section of the 
general elderly population in Western Norway. 
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5.2 Discussion of specific results 
In a large population-based study of elderly people, we found that even though the intake of 
vitamin D rich food items such as fatty fish and cod liver oil were high, the total intake of 
vitamin D in the study population were in general low, and a high portion of the participants 
did not meet the Nordic recommendations. Furthermore, for those that took supplemental 
cod liver oil, the intake was significantly higher than for those who did not. We found a 
significant association between vitamin D intake and cognitive test scores for several of the 
cognitive tests in the test battery (S-task, KOLT, m-DST and Z-score). Moreover, the risk of 
scoring poorly on several cognitive tests increased when the vitamin D intake was low. 
Adjustment for relevant covariates did, however, markedly reduce the strength of the 
association. Also, the results show that cod liver oil intake was not associated with KOLT 
score, but that lean fish and fatty fish both were associated. In addition, we found that for 
non-users of cod liver oil, the risk of scoring poorly on the KOLT was associated with low 
intake of lean fish, while fatty fish, a rich source of vitamin D, did not contribute. 
5.2.1 Intake of vitamin D in the elderly  
The contributing sources of vitamin D were found to be fish and fish products (especially 
fatty fish), cod liver oil and fortified butter/margarines. Our population consumed high 
amounts of vitamin D-containing foods such as cod liver oil and fish and fish products 
compared to other studies [122-124]. 
The vitamin D intake in the present population showed a wide range (0.5 to 56.1µg/d). 
When referring to the Nordic Recommendations, 64.0% were defined as having a low intake 
of vitamin D. According to the American Recommendations for this age group, which is 
≥15.0 µg/d [125] 77.6% would be defined as having a low intake with only 22.4% having an 
adequate intake.  
Intake of vitamin D amongst the elderly populations is lower than the recommended intake 
level in all the Nordic countries [126]. In theory, it is possible to design a diet that would 
meet the recommendations of ≥10 µg/d, but the fact remains that it is difficult to achieve 
these amounts without supplementation [15]. Data from NHANES 1999-2000 showed that 
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total vitamin D intake from food sources across all age groups ranged from 3.8 – 6.9 µg/d, 
and that few older adults did achieve recommended vitamin D intakes [127]. It has been 
proposed by different researchers that elderly with little or no sun light exposure should 
receive a supplement of 10 µg/d in addition to their dietary intake [15, 128, 129]. 
Fortification and supplement use 
In the present population, the users of cod liver oil had a significantly higher intake of 
vitamin D than those that did not take cod liver oil as a supplement. A high percentage 
(76.1%) of those that took cod liver oil as a supplement, did in fact reach the recommended 
intake level of vitamin D. In contrast, only 12.4% of the non-users of cod liver oil reached 
the recommended intake level of vitamin D. 
O’Donnel et al found in their meta-analysis reviewing 11 randomised controlled trials that 
vitamin D fortified foods improved vitamin D status in adults in the United States [130]. 
Furthermore, Calvo et al reported that fortified foods provided 65 – 86% of the total daily 
vitamin D intake from foods [20]. Moore et al found, however, that even though USA fortify 
several foods such as orange juice, milk and yoghurt, margarine, flours and ready-to-eat 
breakfast cereals, the intake is still much lower than the recommended daily allowance 
(RDA) [125]. 
As mentioned in the introduction, there are several challenges for the elderly part of the 
population in regards to reach a satisfactory vitamin D status. Age-related biological 
changes such as a reduced capacity to synthesise vitamin D in the skin as well as a lower 
conversion of the hormone in the kidneys, combined with the fact that this population reside 
in Norway at high latitude where endogenous synthesis is very low many months of the year, 
increase the necessity for an adequate intake. Furthermore, many elders are institutionalised 
and receive little or no sunlight exposure. 
Even though this population had a high intake of vitamin D-containing foods and 
supplements, the majority were defined as having a less than adequate intake. We found that 
for those not taking cod liver oil, fortified foods (butter and margarine) was an important 
source of vitamin D. Furthermore, we found that supplementation in the form of cod liver 
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oil was successful in regards to reaching the recommendations. Our data suggest that 
supplementation combined with fortification would probably be required in order to 
reachthe recommended intake levels of vitamin D. 
5.2.2 Intake of vitamin D and cognitive test performance 
We found that a low intake of vitamin D increased the risk of scoring poorly on several of 
the cognitive tests (KOLT, m-DST, m-MMSE and sum Z-scores). After multiple 
adjustments, the KOLT (episodic memory) and S-task (verbal fluency) remained significant 
for linear regression analysis, whereas only the KOLT was significantly associated with one 
of the quintile intakes of vitamin D in logistic regression analysis.  
An extensive body of evidence supports a role for vitamin D beyond the classical function in 
calcium homeostasis. Epidemiologic observational studies have revealed a beneficial role 
for vitamin D in muscle function, cardiovascular health, diabetes, and cancer prevention [1]. 
More recently, evidence is emerging regarding a potential beneficial role of vitamin D in 
cognitive function [31]. 
Deficiency studies in animal models and epidemiologic investigations have supported a role 
for vitamin D in neurodegenerative disorders such as dementia.  
Biological evidence 
As mentioned in the introduction, vitamin D exhibits functional traits that may prove 
neuroprotective through antioxidative mechanisms, neuronal calcium regulation, immuno-
modulation, enhanced nerve conduction and detoxification mechanisms [54, 56, 70]. The 
vitamin D receptor and catalytic enzymes are co-localized in the areas of the brain involved 
in complex planning, processing, and the formation of new memories [45, 50, 64]. These 
findings potentially link vitamin D to neurocognitive function. 
Whereas some studies have reported no observed impairments in working memory or 
anxiety in the VDR-Knock Out (VDR-KO) model [50], others have been able to show such 
discrepancies in the VDR-KO phenotype. Symptoms such as anxiety-like behaviour and 
behavioural impairment were observed by Kalueff et al [52, 53]. In embryonic animal 
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models it has also been discovered that vitamin D deficiency may result in morphological 
brain changes and memory and learning deficits [49, 131].  
Clinical evidence 
While in vitro and animal models suggest neuroprotective benefits from vitamin D upon 
exposure, there are inconsistencies in the clinical literature related to vitamin D and 
cognitive function in the elderly.  
One case-control study with a substantial cognitive test battery found that there were no 
significant positive association between 25(OH)D concentration and cognitive performance. 
They did however report that a low level of serum 25(OH)D was significantly associated 
with a high depression score [41]. Two other cross-sectional studies did discover significant 
positive associations between serum 25(OH)D and cognitive performance [38, 39]. Another 
study, also with a cross-sectional design, found no significant positive association between 
25(OH)D concentration and cognitive abilities determined from different cognitive tests 
[42]. Oudshoorn et al performed a cross-sectional study and stated that there was a 
significant positive association between 25(OH)D and scores on the Mini Mental State 
Examination [37]. LLewellin et al established in their cross-sectional study by using data 
from the Health Survey for England 2000 (HSE) that low serum 25-hydroxyvitamin D is 
associated with increased odds of cognitive impairment [132]. Slinin et al found little 
evidence of independent associations between lower 25(OH)D levels and baseline global 
and executive cognitive function or incident cognitive decline in their cohort study of 
community dwelling elderly men [133]. 
Buell et al states that to test cognitive function in relation to vitamin D a comprehensive 
cognitive test battery and a large sample size is necessary [31]. They found, using data from 
the NAME study [134], a large cross-sectional study with 1200 participants and an extensive 
test battery, that 25(OH)D was associated with both global and specific aspects of cognitive 
function [135]. 
McCann et al found in their review that even though mechanistic and biological evidence 
strongly suggests that Vitamin D is involved in brain development and critical brain 
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functions, it was difficult to demonstrate obvious effects of vitamin D deficiency on 
cognitive endpoints [136]. They do however conclude from the overall evidence that 
supplementation to ensure adequacy is needed in vulnerable populations such as the elderly 
[136]. 
Annweiler et al performed a meta-analysis reviewing 127 articles where they aimed to 
describe the relationship between vitamin D and the nervous system throughout the different 
stages of life. They state that of the studies reviewed, there are arguments in favour of a life 
long role of vitamin D on the nervous system. They go on to say that in older adults, 
hypovitaminosis D has been associated with neuromuscular disorders, dementia and 
Parkinson’s disease. They conclude that vitamin D has been associated with many 
neurological functions and its deficiency with dysfunction. Low serum 25-hydroxyvitamin D 
concentrations can potentially be reversed. This simple and low-cost correction might 
contribute to the prevention of various neuropsychiatric disorders [137]. 
5.2.3 Intakes of cod liver oil, lean fish and fatty fish in relation to 
cognitive performance 
In theory, if vitamin D is protective of cognitive decline, vitamin D containing foods would 
also have a protective effect on cognition. We found that the food items that contribute 
substantially to the total intake of vitamin D were cod liver oil, fatty fish, and butter and 
margarines. Incidentally, the intake of lean fish is very high in the present population. In this 
cohort, lean fish, which is not a good source of vitamin D appeared to be more important for 
cognitive performance than fatty fish and cod liver oil, both of which are substantial 
providers of vitamin D. 
As mentioned earlier, it has previously been shown in this cohort that effects of fatty fish 
and lean fish on cognition were comparable, but that when restricting the significance level 
to P<0.001 in a multiple adjusted model, only the association between lean fish and the 
KOLT remained (P<0.001) [88]. Data from that same study showed that subjects whose 
mean daily intake of fish and fish products was ≥10 g/d  had significantly better mean test 
scores and a lower prevalence of poor cognitive performance than did those whose intake 
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was <10 g/d. Furthermore, they found that the effect was more pronounced for non-
processed lean fish and fatty fish. They concluded from their study that in the elderly, a diet 
high in fish and fish products is associated with better cognitive performance in a dose-
dependent manner [88]. 
The population in HUSK have an intake of lean fish that is high compared to other studies 
[124, 138]. A diet rich in fish might be part of other lifestyle choices and a dietary pattern 
that is protective of cognitive decline [139, 140]. Data from HUBRO suggest that people 
with higher/more education are more likely to take supplements [129]. In the present 
population, the intake of fish and fish products and supplements were higher for the users of 
cod liver oil. 
Studies have come up with conflicting results when it comes to the protective effects of fish 
and fish oils in regards to cognitive impairment. Dangour et al were not able to show any 
protective effect of fish oil supplements in their randomised controlled trial. The trial only 
ran for 24 months and so it was speculated that the intervention period was too short to show 
any effect [141]. Devore et al found, using data from the Rotterdam study that a moderate 
consumption of fish and omega-3 poly-unsaturated fatty acids (PUFAs) were not associated 
with long term risk of dementia, and that there were little or no difference if the subjects 
consumed fatty fish, lean fish or omega-3 PUFAs [142]. 
A diet high in fish and fish products may replace other unhealthy nutrients such as saturated 
fatty acids from meat. Indeed, studies have found that a dietary pattern that resembles the 
Mediterranean diet, which is high in fish, vegetables, fruits and nuts, olive oil (mono 
unsaturated fatty acids), cereals, low in meat and dairy products, and moderate consumption 
of alcohol, might be protective of cognitive decline [143]. 
Food pattern analysis 
Dietary pattern analysis is a method that makes it possible to examine the relationship 
between diet and the risk of chronic diseases.  Rather than looking at the effects of 
individual nutrients or foods, dietary pattern analysis examines the diet on a whole by 
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applying statistical methods such as factor analysis, cluster analysis and dietary indices 
[144]. 
Dietary patterns represent a broader picture of food and nutrient consumption, and may for 
that reason be more predictive of disease risk than individual foods or nutrients. The present 
study has analysed the intake of vitamin D as a single nutrient in relation to cognitive 
function. There are several limitations in regards to single nutrients or single foods in 
relation to disease. Firstly, people do not eat isolated nutrients. Single nutrients are part of 
food items, food items are ingested as meals, and both foods and meals are complex 
combinations of nutrients that are likely to be interactive or synergistic [145]. Secondly, the 
effect of a single nutrient may be too small to detect, but the cumulative effects of multiple 
nutrients included in a food pattern might be adequately large to be noticeable [146]. Finally, 
as nutrient intakes are commonly associated with certain dietary patterns [147, 148], single 
nutrient analysis may be confounded by the effect of dietary patterns [144]. Adjustment for 
nutritional covariates in multivariate analyses may leave residual confounding effects 
because the dietary components may interact with each other. Dietary pattern analysis may 
serve as a complimentary approach to single nutrient analysis and can be used as a covariate 
when examining a specific nutrient to determine whether the effect of the nutrient is 
independent of the overall dietary pattern [144].  
Observational epidemiological studies are recognising dietary pattern as potentially being 
protective of cognitive decline [143, 149].  
Gu et al examined the effects of dietary pattern in relation to the development of 
Alzheimer’s disease in a cohort consisting of over 2000 community-based elderly New 
Yorkers. They found a strong relationship with a specific dietary pattern and reduced risk of 
developing Alzheimer’s disease. The diet was characterised by higher intakes of salad 
dressing, nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits, and dark and green 
leafy vegetables and a lower intake of high-fat dairy products, red meat, organ meat, and 
butter. They concluded that simultaneous consideration of previous knowledge regarding 
potentially Alzheimer’s-related nutrients and multiple food groups can aid in identifying 
food combinations that are associated with Alzheimer’s risk [139]. 
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6. Conclusions and implications 
In a population-based study with a high intake of vitamin D containing foods, we found that 
the sources that contributed mostly to the total intake of vitamin D were fish and fish 
products, supplements in the form of cod liver oil, and butter and margarines. Furthermore, 
the intake of vitamin D was significantly higher for those that took cod liver oil as a 
supplement. Weak associations between vitamin D intake from foods and supplements, and 
cognitive function were found in both multiple linear and logistic regression analyses. 
Another finding was that for non-users of cod liver oil, a low intake of lean fish was 
associated with having an increased risk of scoring poorly on the KOLT (episodic memory), 
whereas intake of fatty fish or cod liver oil (both of which are rich sources of vitamin D) 
was not significantly associated. From this research project, it remains unclear whether it is 
vitamin D in itself, food items or dietary pattern that is protective when it comes to cognitive 
decline. 
The strengths of the present study were a large sample size as well as a comprehensive 
cognitive test battery. The cross-sectional design together with the lack of 25(OH)D serum 
values serve as substantial limitations.  
Whereas clinical studies show conflicting results, biological evidence supports a role for 
vitamin D in the protection of cognitive decline. Because dementia is a disease that develops 
over time, it seems likely that prevention in the form of diet would have to be life long. The 
pressing need to find preventative measures for this detrimental disease warrants large, long-
term, population-based prospective studies as well as randomized controlled trials using 
both intake data as well as 25(OH)D in serum. Also, perhaps it would be wise to utilise 
dietary pattern analysis in addition to single nutrient analysis. 
Finally, the topic of vitamin D and cognition is relatively new and future studies should aim 
at providing greater understanding of the biological effects of vitamin D on cognitive 
impairment. 
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ABSTRACT 
Background: Increasing evidence suggests that vitamin D may be protective in the development of 
cognitive impairment and dementia in older subjects. 
Objective: To examine the cross-sectional relationship between dietary intake of vitamin D and 
cognitive performance. 
Design: Subjects (n =1916) aged 70-74 years, were recruited from the general population in 
Western Norway and underwent cognitive testing. The cognitive test battery included the Kendrick 
Object Learning Test (KOLT), Trail Making Test (part A), modified versions of the Digit Symbol 
Test, Block Design, Mini-Mental State Examination, and Controlled Oral Word Association Test 
(COWAT). Intake of vitamin D was calculated from a food frequency questionnaire. 
Results: Sixty-four percent of the population did not meet the Nordic recommendations of vitamin 
D intake (≥ 10 µg/d). In adjusted linear regression analyses, only COWAT and KOLT were 
significantly, but weakly associated with intake of vitamin D. Logistic regression analyses showed 
that the risk of scoring poorly on the KOLT was significantly increased when the intake of vitamin 
D was low. Further investigation suggested that a low intake of lean fish in subjects that did not 
consume cod liver oil was associated with increased risk of scoring poorly on the KOLT. 
Conclusions: In the elderly, a low vitamin D intake was associated with increased risk of scoring 
poorly on episodic memory and verbal fluency. In non-users of cod liver oil, episodic memory was 
negatively affected by a low intake of lean fish. Fish as a food item and dietary pattern may be more 
protective when it comes to cognitive decline than vitamin D as a single nutrient. 
KEY WORDS Cognitive deficit, cognition, elderly, vitamin D, cholecalciferol 
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INTRODUCTION 
Vitamin D deficiency causes rickets and ostemalacia [1]. In recent years, observational studies have 
shown that an optimal vitamin D status may also be associated with reduced risk of autoimmune 
diseases, diabetes type 2, cancer, cardiovascular disease (CVD) and cognitive impairment [2-6]. 
Vitamin D is a pro-hormone that is produced in the skin through a photolytic process induced by 
sunlight exposure (UVB 290-320 nm) [7]. There are two forms of vitamin D; cholecalciferol 
(vitamin D3) and ergocalciferol (vitamin D2). Vitamin D3 is produced in the skin and it also occurs 
naturally in a small range of foods, whereas vitamin D2 derives from plants and yeast. Through two 
enzymatically regulated hydroxylation reactions active vitamin D (1,25-dihydroxyvitamin D, 
calcitriol) is produced in the liver and kidney, respectively [8]. 
Elderly are at particular risk for developing vitamin D deficiency due to reduced capacity to 
synthesise vitamin D in the skin [9]. Also, many elderly are institutionalised and therefore less 
exposed to sunlight [10]. It has been estimated that 40-90% of the elderly worldwide have vitamin 
D insufficiency (<75 nmol/L) [11]. In addition, people living in high latitudes often have a reduced 
endogenous production of vitamin D as the UV wavelengths are less than optimal for dermal 
production of the vitamin [12]. These findings suggest that an increase in vitamin D intake may be 
necessary in this section of the population. 
Vitamin D in the diet is almost solely found in fatty fish and fish oils [7]. Supplementation and 
fortification are important contributors to the total intake of vitamin D [13]. 
Studies have confirmed that an increase in vitamin D intake leads to an increase of vitamin D in 
serum [14-16]. This present study focuses on the intake of vitamin D in relation to cognition in 
older subjects using data from the Hordaland Health Study (HUSK), a population with high intake 
of fish and fish oils.  
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SUBJECTS AND METHODS 
Study population 
The HUSK study was conducted from 1997 to 1999 as a collaboration between the University of 
Bergen, University of Oslo, local health services, and the Norwegian Institute of Public Health. In a 
subsample of the study, 4338 individuals born in 1925–1927 who had participated in the Hordaland 
Homocysteine Study in 1992–1993 [17], were re-invited to participate in HUSK. Recruitment into 
the Cognitive Sub-study is described on the Web (Internet: 
www.uib.no/isf/husk/Vedlegg_dokumenter/Cognitive_Sub_study.pdf). A total of 2155 subjects 
completed the cognitive test battery. Of those, 1991 individuals completed a food-frequency 
questionnaire (FFQ). Participants with a very low energy intake (< 3000 kJ for women; < 3300 kJ 
for men), or very high energy intake (≥ 15000 kJ for women; ≥ 17500 for men) were excluded from 
the analyses [18], leaving a total of 1916 subjects that were included in the present study. All 
participating subjects gave their written informed consent. The study protocol was approved by the 
Regional Committee for Medical Research Ethics of Western Norway.  
Data collection 
Cognitive testing was performed at the study location by trained nurses after the standard 
cardiovascular examinations of the National Health Screening Service were completed [17]. The 
cognitive test battery included 6 tests. The abridged version of the Controlled Oral Word 
Association Test (COWAT, called also S-task), a test of verbal fluency and psychomotor speed 
[19]; the Kendrick Object Learning Test (KOLT), a test of episodic memory [20]; the modified 
version of the Digit Symbol Test (m-DST) which was designed to measure focused attention, 
visuomotor coordination, and psychomotor speed [21]; the Trail Making Test part A (TMT-A), a 
test of visual conceptual and visuomotor tracking [22]; the modified version of the Block Design 
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test (m-BD), a test of visuospatial and motor skills [21]; and lastly, the modified version of the 
Mini-Mental State Examination (m-MMSE) which is a test of global cognition [23]. Z-scores were 
calculated for all of the tests except for the m-MMSE, and combined together into one variable. 
This sum Z-score variable represents global cognition, but in contrast to m-MMSE it has the 
advantage of being normally distributed, and without ceiling effect. 
Dietary habits 
To assess habitual food composition, a modified version of a comprehensive FFQ created at the 
Department of Nutrition, University of Oslo [24], was handed out on the day of the examination and 
filled out later at home by the participants and then mailed to the HUSK project Centre in Bergen. 
The FFQ was designed to give information about food intake during the past year. The 
questionnaire included 169 food items that were grouped according to Norwegian meal patterns. 
The frequency of consumption was given per day, week, or month. The portion sizes were given as 
household measures or units such as slices or pieces. In addition to food groups the questionnaire 
also included questions about dietary supplement intake, in which the product names of the most 
used supplements in Norway were considered. The use of cod liver oil was reported as seasonal use 
(during the whole year or only winter half of the year), frequency per week, and amount per time. 
The subjects were advised to estimate an “average” of amounts of food. The intake per person 
according to food group and nutrients was calculated by the use of a food database and software 
system developed at the Department of Nutrition, University of Oslo (Kostberegningssystem, KBS, 
version 3.2; University of Oslo, Oslo, Norway) [24]. The FFQ has been validated in several studies 
[24, 25]. 
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Covariates 
At baseline, participants underwent the standard cardiovascular examinations of the National Health 
Service. Several self-administered questionnaires focusing on cardiovascular risk factors, lifestyle 
factors, and dietary habits were used.  A history of CVD was defined as self-reported information at 
baseline, or during follow-up from 1992-1999. On the basis of information from both surveys, the 
subjects were categorized as with or without a history of CVD. A history of diabetes was self-
reported.  
Educational level was self-reported and recorded in 6 categories: Not completed primary school, 
primary school (9 years), technical college (10-12 years), secondary school (10-12 years), and 
college or university less than 4 years and more than 4 years. Non-fasting EDTA blood samples 
were collected for the measurement of total homocysteine (tHcy), creatinine and gene 
polymorphisms. Plasma tHcy was measured by using a fully automated HPLC assay [26]. 
Apolipoprotein E (ApoE) ε4 genotypes were determined in the packed cell fraction of blood 
samples by using a one-stage polymerase chain reaction method [27]. Creatinine was measured in 
stored plasma by a modification of a liquid chromatography-mass spectrometry described 
previously [28]. 
The Hospital Anxiety and Depression Scale was used to assess depression (HADS-D) and anxiety 
(HADS-A) through a self administered questionnaire [29]. In this study, only the HADS-D score 
was used as it is more relevant to cognitive function [30]. When tested, HADS-A was not associated 
with vitamin D. 
The smoking variable was coded as number of cigarettes smoked per day. Blood pressure was 
measured three times, and the variable used in this study is the average of the second and third 
measurement. 
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Age is not included due to the narrow age span of the participants. 
Statistical Analyses 
All calculations were performed by using SPSS 16.0 (SPSS INC, Chicago IL) unless otherwise 
stated. Results are expressed as medians with 25th and 75th percentiles or means with standard 
deviations (SD). Pearson’s chi-square test and Student’s t-test were used to examine relationships 
between independent groups. For comparisons between intakes of vitamin D containing foods in 
users and non-users of cod liver oil ANOVA was used. Spearman’s rho correlation coefficients 
were used to assess simple correlations. Multiple linear and logistic regression analyses were 
performed to examine relationships between intake of vitamin D (entered as quintiles) and the 
cognitive test scores adjusted for relevant covariates.  In logistic regression analysis, categories of 
intake were chosen to examine whether a low intake would increase the risk of scoring poorly on a 
cognitive test using the highest quintile as reference (vitamin D intake ≥ 15.7 µg/d). A poor 
cognitive test score was set to the ~10th percentile for all the tests, except for the TMT-A, where the 
90th percentile was used [31]. To avoid over-adjustment, three regression models were routinely 
used; first adjusting for sex only, then two with multiple adjustments. When adjusting for potential 
confounders, we adjusted only for recognized determinants of cognitive function (e.g. education, 
ApoE ε4 allele status) or for variables that were significantly associated with 4 or more of the 
cognitive tests (including sum Z-score) as well as vitamin D intake in our data set. In the second 
model, which is presented in the text throughout the paper, the following variables were included: 
sex (men or women), education (6 categories), ApoE variant ε4 allele (presence or not presence), 
tHcy (quintiles), and total energy intake (quintiles). The third model included also nutritional 
covariates (quintiles) in addition to the aforementioned variables: intakes of fruits, cereals, meat and 
meat products, vegetables, sweets, tea, and wine. We assessed the association between month of 
cognitive testing and the cognitive scores. For several of the tests, we found the lowest score in 
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August and September. However, adjusting for this variable did not change the results and it was 
omitted from the analyses. 
We have previously shown in this cohort that intake of both fatty fish and lean fish is associated 
with improved cognition [31]. In our population, cod liver oil provided a unique source of vitamin 
D. We therefore further explored the relationship between cognition (KOLT), lean fish and fatty fish 
by splitting the population into users and non-users of cod-liver oil. In a logistic regression analysis, 
the cognition variable was entered as dependent variable (dichotomous, 10th percentile as cut-off) 
and intake of lean fish (4 categories: 0, 0.1 – 25.0, 25.1 – 50.0 and ≥ 50.1 g/d) and fatty fish (4 
categories: 0, 0.1 – 10.0, 10.1 – 20.0 and ≥ 20.1 g/d) was entered as indicator variables. For both 
types of fish, the highest intake group was used as reference. In addition to adjust for lean fish and 
fatty fish mutually, we also adjusted for sex, education, ApoE ε4 variant allele, tHcy and total 
energy intake. The same analysis was also conducted but including cod liver oil (0, 0.1 – 2.5, ≥ 2.6 
g/d) as indicator variable, instead of using it as a selection variable.  
All P-values are 2-sided, and values < 0.05 were considered significant.  
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RESULTS  
Subject Characteristics, cognitive performance and dietary intake 
The total number of participants included was 1916 (883 men and 1033 women), all born within the 
timeframe 1925-1927. The intake of vitamin D in the present population ranged from 0.5 to 56.1 
µg/d, with a median of 7.3 µg/d (25th and 75th percentiles: 4.1,13.9). Sixty-four percent of the 
population did not meet the Nordic recommendations of vitamin D intake (≥10 µg/d) [32]. When 
defining a low cognitive test score as the tenth percentile (90th for the TMT-A), only 3 subjects 
were defined as scoring poorly on all of the cognitive tests, whereas 678 participants (35.4%) scored 
poorly on at least one test. 
Comparisons of adequate vs. low intake of vitamin D 
More men than women were significantly classified as having an adequate intake of vitamin D, i.e., 
≥10 µg/d  (Table 1). The educational level as well as total energy intake was significantly higher in 
the adequate intake group compared to the low intake group. Three of the cognitive tests (COWAT, 
m-DST, m-MMSE) and the Z-score were significantly higher in the adequate intake group 
compared to the low intake group. Plasma tHcy was significantly higher in the low intake group. 
Plasma creatinine was borderline significantly higher in the adequate intake group. There was no 
significant difference in smoking status, BMI, blood pressure, CVD or diabetes history or ApoE ε4 
variant allele profile when comparing the two intake groups. 
Dietary sources of vitamin D  
Table 2 shows the contribution of vitamin D from the most important sources of vitamin D in the 
total population. Fish was the main contributor of vitamin D, with fatty fish as the most important 
source within the fish group. Fortified butter/margarines were the second most important source. 
Supplements were also an important contributor of vitamin D, with cod liver oil as the main 
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provider. Thus, dietary vitamin D derived mainly from fish, fortified butter/margarines and 
supplements, with these three products providing 93.2 % of total vitamin D intake. When we 
separated the group into users and non-users of cod liver oil, it became apparent that for the non-
users, fish (total intake) contributed mostly to the total vitamin D intake with 46.4 (SD: 24.0) %, but 
that for the cod liver oil users, the cod liver oil was the most important source contributing with 
50.8 (SD: 25.7) % (Table 1S). Also, for those taking cod liver oil as a supplement, the contribution 
of vitamin D from butter/margarines was much lower than for the non-user group (Table 1S). 
Covariates associated with cognition and vitamin D 
Associations between relevant dichotomous variables, cognitive test scores and vitamin D intake are 
presented in Table 2S. Men scored significantly better on the TMT-A and women scored better on 
the KOLT. No other tests differed according to sex. Men had a higher intake of vitamin D than 
women. ApoE ε4 variant allele was associated with significantly lower test scores for KOLT, m-
MMSE, m-DST and Z-score. Vitamin D intake was not significantly associated with ApoE ε4 
variant allele profile. The COWAT, KOLT and Z-score were significantly poorer for those with a 
history of CVD. The COWAT, KOLT, m-DST and Z-score were significantly higher for the 
subjects without diabetes. Because CVD and diabetes were not significantly associated with vitamin 
D, these variables were not included in the final analyses. 
Spearman’s Rho correlation coefficients between continuous variables, the cognitive tests and 
vitamin D intake are shown as supplemental data Table 3S. Vitamin D intake was correlated with 
COWAT, m-DST, m-MMSE, TMT-A and sum Z-score in addition to education, tHcy, creatinine, 
total energy intake and all of the food groups. At least four of the cognitive tests including sum Z-
score were significantly associated with the following variables: Education, intake of total energy, 
depression score, vitamin D containing supplements, fish total (including all fish and fish products), 
lean fish, fatty fish, dairy products, fruit, meat and meat products, cereals, vegetables, sweets and 
 96 
drinks (tea and wine). Coffee consumption was not correlated with vitamin D intake (data not 
shown). Among the nutritional variables, fruit, meat and meat products, cereals, vegetables, sweets 
and drinks did not contain vitamin D and were considered potential confounders. Smoking, blood 
pressure, HADS-D score, creatinine and BMI were associated with less than four of the cognitive 
tests and/or not associated with vitamin D and were therefore not included in further analyses. 
Linear regression analyses 
Linear regression analyses adjusted for sex indicated that a significant association between quintiles 
of vitamin D intake as independent variable and the COWAT, KOLT, m-DST, m-MMSE or the 
sum Z-score as dependent variable existed (Table 3). After additional adjustment with ApoE ε4 
variant allele, education, tHcy, and energy intake, the COWAT and KOLT remained significantly 
associated with intake of vitamin D (Table 3). The association was markedly reduced compared to 
the sex-adjusted model, and it appeared that it was inclusion of education and total energy intake 
that accounted for the weakening of the association. In the final model, including adjustment for 
nutrients, none of the cognitive tests remained significant.  
Risk of poor cognitive test performance according to intake of vitamin D  
Using logistic regression, we first investigated the risk of scoring poorly on a cognitive test 
according to quintiles of total vitamin D intake. The upper quintile of vitamin D was used as the 
reference category. 
In the model adjusted only for sex, when comparing the highest and lowest quintiles of vitamin D 
intake, there was an increase in risk for scoring poorly on the KOLT (OR = 1.74, 95 % CI: 1.08, 
2.08), m-DST (OR = 1.90, 95 % CI: 1.11, 3.26), m-MMSE (OR = 1.40, 95 % CI: 0.84, 2.32), and 
the sum Z-score (OR = 1.74, 95 % CI:1.07, 2.83) , Ptrend < 0.05 for all. 
             97 
In the multiple adjusted model, none of the tests remained significant (Table 4). However, those 
with vitamin D intake in the lowest quintile had significant increased odds ratio for scoring poorly 
on KOLT (OR = 1.81, 95 % CI: 1.04, 3.15). Further adjusting for additional nutrients marginally 
weakened the results (OR = 1.65, 95 % CI: 0.94, 2.89).  
Sources of vitamin D vs. lean fish 
As previously mentioned, an earlier study conducted on this cohort revealed an association between 
lean fish intake and the KOLT [31]. In the present study, we found that the KOLT was the only 
cognitive test that was significantly associated with vitamin D intake in both linear and logistic 
regression analyses in Model 2. The mean intakes of vitamin D, lean fish, fatty fish and fish total 
were all significantly higher in the user group of cod liver oil compared non-users (all P-values 
<0.001) (Table 1S). The amounts in grams however do not differ to a large extent, but the values 
become significant as a result of our large sample size. Among non-users of cod liver oil, the risk of 
scoring poorly on the KOLT increased when the intake of lean fish was low (0.1 g/d – 25.0 g/d, P = 
0.027). When further adjusted for butter/margarines and other kinds of fish and fish products, the 
model weakened, but the same intake category for lean fish (0.1 – 25.0 g/d) stayed significant (OR = 
1.82, 95 % CI: 1.01, 3.28, Ptrend = 0.030). No significant relationship was found when the same 
analysis was performed with fatty fish. We also tested for interaction between cod liver oil and fish 
intake: there was no significant interaction for fatty fish, but a borderline association for lean fish 
(P=0.072). When including  cod liver oil in the model as an indicator variable, the risk of scoring 
poorly on the KOLT in fully adjusted model, low intake of lean fish was almost significant (0.1 – 
25.0 g/d, OR = 1.57, 95 % CI: 0.99, 2.49, P = 0.054), whereas cod liver oil intake and fatty fish 
intake were not significantly associated.  
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DISCUSSION 
In a large population-based study of elderly people living at high latitudes in a rainy climate, we 
found a significant association between vitamin D intake and cognitive test scores in several of the 
cognitive tests in the test battery (COWAT, KOLT, m-DST and Z-score). Furthermore, we found 
that the risk of scoring poorly on several cognitive tests increased when the vitamin D intake was 
low. However, adjustment for relevant covariates markedly reduced the strength of the association. 
In addition, we found that for non-users of cod liver oil, the risk of scoring poorly on the KOLT was 
associated with low intake of lean fish, while fatty fish, a rich source of vitamin D, did not 
contribute significantly. 
Intake of vitamin D and current recommendations 
The vitamin D intake in the present population showed a wide range (0.5 to 56.1 µg/d). If we use 
the Nordic Recommendations, 64.0% were defined as having a low intake of vitamin D. According 
to the American Recommendations for this age group, which is ≥15.0 µg/d [33], 77.6 % would be 
defined as having a low intake with only 22.4% having an adequate intake. Our population 
consumed high amounts of vitamin D containing foods such as cod liver oil and fish and fish 
products compared to other studies [34, 35]. O’Donnel et al found in their meta-analysis reviewing 
11 randomised controlled trials that vitamin D fortified foods improved vitamin D status in adults in 
the United States. Data from NHANES 1999-2000 showed that total vitamin D intake from food 
sources across all age groups ranged from 3.8 – 6.9 µg/d, and that few older adults achieve 
recommended vitamin D intakes [36]. Furthermore, fortified foods provided 65 – 86 % of the total 
daily vitamin D intake from foods [13]. The United States fortify several foods such as orange juice, 
milk and yoghurt, margarine, flours and ready-to-eat breakfast cereals, and yet the intake is still 
much lower than the recommended daily allowance (RDA) [37]. Even though our population have a 
high intake of vitamin D containing foods and supplements, the majority were defined as having a 
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less than adequate intake. This would indicate that reaching the RDA is difficult, and measures need 
to be taken to ensure an adequate intake in the population. We found that for those not taking cod 
liver oil, fortified foods (butter and margarine) was an important source of vitamin D. The use of 
fortification and supplements together will probably be required. Mosekilde speculate that one of 
the reasons as to why serum levels in the USA have a higher range than Europe [38] is because of 
the liberal fortification politics in Northern America compared to Europe [39]. 
Intake of vitamin D and cognitive test performance 
We found that a low intake of vitamin D increased the risk of scoring poorly on several of the 
cognitive tests (COWAT, KOLT, m-DST, m-MMSE and sum Z-scores). However, after multiple 
adjustments, only the KOLT (episodic memory) and COWAT (semantic memory) remained 
significant but weaker in linear associations. None of the tests were significant when the risk for 
poor test performance was assessed. Several studies have shown an association with vitamin D in 
serum and cognitive decline [6, 40, 41], these are, however, observational studies, and so far 
evidence based on randomized clinical trials is lacking. Furthermore, some studies have found no 
relationship between serum vitamin D concentrations and cognition [42, 43]. A review article by 
Annweiler et al reviewed 5 cross sectional studies that had looked into the relationship between 
serum 25(OH)D and cognition [44]. They found the evidence to be inconclusive. 
Fatty fish, lean fish, cod liver oil and cognitive performance 
The best sources of vitamin D in our study were fatty fish and cod liver oil. These products contain 
not only vitamin D, but a number of other important nutrients that have been associated with 
cognition, essential fatty acids being among them [45]. Studies have come up with conflicting 
results when it comes to the intake of essential fatty acids, fish intake and cognition [46-48]. 
Dangour et al were not able to show any protective effect of fish oil supplements in their 
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randomised controlled trial. The trial only ran for 24 months and so it was speculated that the 
intervention period was too short to show any effect [49]. Devore et al found, using data from the 
Rotterdam study that a moderate consumption of fish and omega-3 polyunsaturated fatty acids 
(PUFAs) were not associated with long term risk of dementia, and that there were little or no 
difference if the subjects typically consumed fatty fish, lean fish or omega-3 PUFAs [48]. 
In theory, if vitamin D is protective of cognitive decline, vitamin D containing foods would also 
have a protective effect on cognition. We found that the food items that contribute substantially to 
the total intake of vitamin D were cod liver oil, fatty fish, and butter and margarines. Also, the 
intake of lean fish was very high in the present population. Interestingly, a high intake of lean fish, 
which is not high in vitamin D, was more strongly associated with cognitive performance than fatty 
fish and cod liver oil. 
A diet rich in fish might be a part of other lifestyle choices and a dietary pattern that is protective of 
cognitive decline [50]. Furthermore, a diet high in fish and fish products may replace other 
unhealthy nutrients such as saturated fatty acids from meat. And indeed, studies have found that a 
dietary pattern that resembles the Mediterranean diet, which is high in fish, vegetables, fruits and 
nuts, olive oil (mono unsaturated fatty acids), cereals, low in meat and dairy products, and moderate 
consumption of alcohol, might be protective of cognitive decline [50]. 
Strengths and limitations 
The strengths of this study are the large number of participants as well as an extensive battery of 
cognitive tests. The large test battery made it possible to test which aspects of cognition that might 
be more affected than others. Because 71% of the study participants volunteered for cognitive 
testing, recruitment bias may have been an issue. Several differences between those who underwent 
and who did not undergo cognitive testing were reported earlier [51]. However, the dietary habits 
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were similar, and the intake of vitamin D was to a large extent the same. In this study we have used 
data that gives an estimated intake of vitamin D calculated from a self-administered FFQ. The FFQ 
has been validated in several studies [24, 25], however not with serum vitamin D as a biomarker. 
People suffering from cognitive ailments might have changed their diet as a result of the disease, 
and self reported dietary data collected from people who are cognitively impaired may be less 
reliable. However, because these were free-living subjects and the vast majority were not impaired, 
we do not think this had major impact on our findings. 
Conclusion 
In a population-based cross-sectional study, we found weak associations between vitamin D intake 
from foods and supplements, and cognitive performance. Also, we found that for non-users of cod 
liver oil, a low intake of lean fish was associated with having an increased risk of scoring poorly on 
the KOLT (episodic memory), whereas a low intake of fatty fish had no risk associated with it. It 
remains unclear whether it is vitamin D itself, food items or dietary pattern that is protective when it 
comes to cognitive performance. Future studies exploring the relationship between cognition and 
dietary pattern are certainly warranted. 
  
 102 
REFERENCES 
1. Grant, W.B., Epidemiology of disease risks in relation to vitamin D insufficiency. Prog 
Biophys Mol Biol, 2006. 92(1): p. 65-79. 
2. Adorini, L. and G. Penna, Control of autoimmune diseases by the vitamin D endocrine 
system. Nat Clin Pract Rheumatol, 2008. 4(8): p. 404-12. 
3. Knekt, P., et al., Serum vitamin D and subsequent occurrence of type 2 diabetes. 
Epidemiology, 2008. 19(5): p. 666-71. 
4. Zittermann, A., S.S. Schleithoff, and R. Koerfer, Putting cardiovascular disease and vitamin 
D insufficiency into perspective. Br J Nutr, 2005. 94(4): p. 483-92. 
5. Tuohimaa, P., et al., Does solar exposure, as indicated by the non-melanoma skin cancers, 
protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer, 2007. 43(11): 
p. 1701-12. 
6. Oudshoorn, C., et al., Higher serum vitamin D3 levels are associated with better cognitive 
test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord, 2008. 
25(6): p. 539-43. 
7. Wang, S., Epidemiology of vitamin D in health and disease. Nutr Res Rev, 2009. 22(2): p. 
188-203. 
8. DeLuca, H.F., Overview of general physiologic features and functions of vitamin D. Am J 
Clin Nutr, 2004. 80(6 Suppl): p. 1689S-96S. 
9. Heaney, R.P., Barriers to optimizing vitamin D3 intake for the elderly. J Nutr, 2006. 136(4): 
p. 1123-5. 
10. Holick, M.F., L.Y. Matsuoka, and J. Wortsman, Age, vitamin D, and solar ultraviolet. 
Lancet, 1989. 2(8671): p. 1104-5. 
11. Cherniak, E.P., et al., Hypovitaminosis D in the elderly: from bone to brain. J Nutr Health 
Aging, 2008. 12(6): p. 366-73. 
12. Holick, M.F., et al., Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res, 
2007. 22 Suppl 2: p. V28-33. 
13. Calvo, M.S., S.J. Whiting, and C.N. Barton, Vitamin D fortification in the United States and 
Canada: current status and data needs. Am J Clin Nutr, 2004. 80(6 Suppl): p. 1710S-6S. 
14. Aloia, J.F., et al., Vitamin D intake to attain a desired serum 25-hydroxyvitamin D 
concentration. Am J Clin Nutr, 2008. 87(6): p. 1952-8. 
15. Heaney, R.P., et al., Human serum 25-hydroxycholecalciferol response to extended oral 
dosing with cholecalciferol. Am J Clin Nutr, 2003. 77(1): p. 204-10. 
16. Ryan, P.J., Vitamin D therapy in clinical practice. One dose does not fit all. Int J Clin Pract, 
2007. 61(11): p. 1894-9. 
             103 
17. Refsum, H., et al., The Hordaland Homocysteine Study: a community-based study of 
homocysteine, its determinants, and associations with disease. J Nutr, 2006. 136(6 Suppl): p. 
1731S-1740S. 
18. Berstad, P., et al., Dietary fat and plasma total homocysteine concentrations in 2 adult age 
groups: the Hordaland Homocysteine Study. Am J Clin Nutr, 2007. 85(6): p. 1598-605. 
19. Benton, A. and K. Hamsher, Multilingual Aphasia Examination. 1989, Iowa: AJA 
Associates. 
20. Kendrick, D., Kendrick cognitive tests for the elderly. 1985: Windsor, United Kingdom: The 
NFER-NELSON publishing company Ltd. 
21. Weschler, D., Weschler Adult intelligence scale - revised. 1981: New York, NY: The 
Psychological corporation. 
22. Reitan, R., Validity of the trail making test as an indicator of organic brain damage. Percept 
Mot Skills, 1958. 8: p. 7. 
23. Braekhus, A., K. Laake, and K. Engedal, The Mini-Mental State Examination: identifying 
the most efficient variables for detecting cognitive impairment in the elderly. J Am Geriatr 
Soc, 1992. 40(11): p. 1139-45. 
24. Andersen, L.F., et al., Evaluation of a food frequency questionnaire with weighed records, 
fatty acids, and alpha-tocopherol in adipose tissue and serum. Am J Epidemiol, 1999. 
150(1): p. 75-87. 
25. Andersen, L.F., K. Solvoll, and C.A. Drevon, Very-long-chain n-3 fatty acids as biomarkers 
for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr, 1996. 64(3): p. 305-11. 
26. Fiskerstrand, T., et al., Homocysteine and other thiols in plasma and urine: automated 
determination and sample stability. Clin Chem, 1993. 39(2): p. 263-71. 
27. Wenham, P.R., W.H. Price, and G. Blandell, Apolipoprotein E genotyping by one-stage 
PCR. Lancet, 1991. 337(8750): p. 1158-9. 
28. Holm, P.I., et al., Determination of choline, betaine, and dimethylglycine in plasma by a 
high-throughput method based on normal-phase chromatography-tandem mass spectrometry. 
Clin Chem, 2003. 49(2): p. 286-94. 
29. Zigmond, A.S. and R.P. Snaith, The hospital anxiety and depression scale. Acta Psychiatr 
Scand, 1983. 67(6): p. 361-70. 
30. Ganguli, M., et al., Depressive symptoms and cognitive decline in late life: a prospective 
epidemiological study. Arch Gen Psychiatry, 2006. 63(2): p. 153-60. 
31. Nurk, E., et al., Cognitive performance among the elderly and dietary fish intake: the 
Hordaland Health Study. Am J Clin Nutr, 2007. 86(5): p. 1470-8. 
32. Nordic nutrition recommendations: NNR 2004 : integrating nutrition and physical activity. 
NORD. 2004, [København]: Nordisk Ministerråd. 435 s. 
 104 
33. Moore, C., et al., Vitamin D intake in the United States. J Am Diet Assoc, 2004. 104(6): p. 
980-3. 
34. Kalmijn, S., et al., Dietary intake of fatty acids and fish in relation to cognitive performance 
at middle age. Neurology, 2004. 62(2): p. 275-80. 
35. Morris, M.C., et al., Fish consumption and cognitive decline with age in a large community 
study. Arch Neurol, 2005. 62(12): p. 1849-53. 
36. Zadshir, A., et al., The prevalence of hypovitaminosis D among US adults: data from the 
NHANES III. Ethn Dis, 2005. 15(4 Suppl 5): p. S5-97-101. 
37. Calvo, M.S. and S.J. Whiting, Prevalence of vitamin D insufficiency in Canada and the 
United States: importance to health status and efficacy of current food fortification and 
dietary supplement use. Nutr Rev, 2003. 61(3): p. 107-13. 
38. Lips, P., Vitamin D deficiency and secondary hyperparathyroidism in the elderly: 
consequences for bone loss and fractures and therapeutic implications. Endocr Rev, 2001. 
22(4): p. 477-501. 
39. Mosekilde, L., Vitamin D and the elderly. Clin Endocrinol (Oxf), 2005. 62(3): p. 265-81. 
40. Przybelski, R.J. and N.C. Binkley, Is vitamin D important for preserving cognition? A 
positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. 
Arch Biochem Biophys, 2007. 460(2): p. 202-5. 
41. Wilkins, C.H., et al., Vitamin D deficiency is associated with low mood and worse cognitive 
performance in older adults. Am J Geriatr Psychiatry, 2006. 14(12): p. 1032-40. 
42. Jorde, R., et al., Neuropsychological function in relation to serum parathyroid hormone and 
serum 25-hydroxyvitamin D levels. The Tromso study. J Neurol, 2006. 253(4): p. 464-70. 
43. McGrath, J., et al., No association between serum 25-hydroxyvitamin D3 level and 
performance on psychometric tests in NHANES III. Neuroepidemiology, 2007. 29(1-2): p. 
49-54. 
44. Annweiler, C., et al., Vitamin D and cognitive performance in adults: a systematic review. 
Eur J Neurol, 2009. 16(10): p. 1083-9. 
45. Luchsinger, J.A., J.M. Noble, and N. Scarmeas, Diet and Alzheimer's disease. Curr Neurol 
Neurosci Rep, 2007. 7(5): p. 366-72. 
46. Kalmijn, S., et al., Dietary fat intake and the risk of incident dementia in the Rotterdam 
Study. Ann Neurol, 1997. 42(5): p. 776-82. 
47. Engelhart, M.J., et al., Diet and risk of dementia: Does fat matter?: The Rotterdam Study. 
Neurology, 2002. 59(12): p. 1915-21. 
48. Devore, E.E., et al., Dietary intake of fish and omega-3 fatty acids in relation to long-term 
dementia risk. Am J Clin Nutr, 2009. 90(1): p. 170-6. 
             105 
49. Dangour, A.D., et al., Effect of 2-y n-3 long-chain polyunsaturated fatty acid 
supplementation on cognitive function in older people: a randomized, double-blind, 
controlled trial. Am J Clin Nutr. 
50. Gu, Y., et al., Food Combination and Alzheimer Disease Risk: A Protective Diet. Arch 
Neurol. 
51. Nurk, E., et al., Plasma total homocysteine and memory in the elderly: the Hordaland 
Homocysteine Study. Ann Neurol, 2005. 58(6): p. 847-57. 
Table 1. Characteristics 
            
  Adequate (≥ 10 µg)  Low (< 10 µg)  
  n n (%) or mean (SD) n n (%) or mean (SD) P-value1 
Sex (male) 690 393 (57.0) 1226 490 (40.0) <0.001 
Education ≤9 y 651 205 (31.5) 1128 460 (40.8) <0.001 
Daily smoker (yes) 690 91 (13.2) 1225 156 (12.7) 0.866 
Number of cigarettes/d amongst smokers 91 9.5 (4.5) 156 10.6 (7.9) 0.638 
BMI 690 25.9 (3.7) 1223 26.2 (4.0) 0.182 
Total energy (kJ) 690 8671 (2272) 1226 6964 (2062) <0.001 
Vitamin D (µg/d) 690 18.8 (7.6) 1226 5.1 (2.4) <0.001 
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Systolic blood pressure 690 146 (21) 1226 146 (20) 0.928 
Diastolic blood pressure 690 78 (12) 1226 77 (12) 0.160 
History of CVD (yes) 677 216 (31.9) 1192 411 (34.5) 0.279 
Diabetes (yes) 678 39 (5.8) 1211 85 (7.5) 0.332 
Depression score 664 3.3 (2.7) 1129 3.6 (2.8) 0.085 
      
Cognitive test scores      
COWAT 690 15.0 (5.3) 1226 15.8 (5.7) 0.001 
KOLT 690 35.2 (8.2) 1226 35.8 (7.6) 0.097 
m-DST 690 10.2 (4.2) 1226 10.8 (4.3) 0.002 
m-MMSE 690 11.5 (0.8) 1226 11.6 (0.7) 0.047 
TMT-A 690 57 (33) 1226 54 (32) 0.074 
m-BD 690 15.1 (2.2) 1226 15.1 (2.1) 0.692 
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Z-score 690 0.96 (0.98) 1226 -0.05 (1.01) 0.002 
      
Plasma variables and ApoE ε4 variant allele status      
tHcy (µmol/L) 690 11.7 (3.6) 1221 12.1 (3.9) 0.027 
Creatinine (µmol/L) 690 78.3 (19.4) 1219 76.4 (18.6) 0.053 
ApoE (ε4 variant allele present) 
686 214 (31.2) 1216 392 (32.2) 0.645 
      
1 Pearson X2- test with continuity correction or Students t-test 
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Table 2. Mean and median intakes of vitamin D from different food groups, as well as the relative contribution of vitamin D intake from the 
different food groups in the total population.  
    
Total population (n = 1916) 
  Mean (SD) Median (25th and 75th percentile) 
 Mean percent contribution 
(SD) 
Supplements total    
Total intake (g/d) 2.1 (3.5) 0 (0, 2.8)  
Vitamin D (µg/d) 4.2 (7.1) 0 (0, 6.05) 23.4 (31.3) 
Cod liver oil    
Total intake (g/d) 1.7 (3.0) 0 (0, 2.0)  
Vitamin D (µg/d) 3.6 (6.5) 0 (0, 4.3) 18.8 (29.1) 
Supplements rest    
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Total intake (g/d) 0.4 (1.6) 0 (0, 0)  
Vitamin D (µg/d) 0.6 (2.1) 0 (0, 0) 4.6 (13.9) 
Fish total    
Total food intake (g/d) 88.6 (55.5) 80.3 (49.6, 116)  
Vitamin D (µg/d) 3.4 (3.2) 2.5 (1.1, 4.6) 38.3 (24.4) 
Fish fatty    
Total food intake (g/d) 14.7 (16.9) 9.3 (2.4, 20.9)  
Vitamin D (µg/d) 2.1 (2.4) 1.3 (0.4, 3.1) 22.8 (20.9) 
Fish lean    
Total food intake (g/d) 36.6 (29.4) 29.7 (15.0, 50.5)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3) 3.2 (3.6) 
Fish rest    
Total food intake (g/d) 37.7 (29.2) 32.4 (18.3, 49.2)  
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Vitamin D (µg/d) 1.1 (1.4) 0.7 (0.1, 1.5) 12.3 (13.2) 
Butter1    
Total food intake (g/d) 26.1 (17.3) 23.4 (13.1, 35.3)  
Vitamin D (µg/d) 2.0 (1.2) 1.8 (1.1, 2.7) 31.5 (22.0) 
Eggs    
Total food intake (g/d) 15.8 (11.5) 15.3 (7.7, 19.4)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3) 3.9 (5.0) 
Dairy products2    
Total food intake (g/d) 343 (206) 321 (195, 458)  
Vitamin D (µg/d) 0.1 (0.1) 0.1(0.1, 0.2) 2.4 (7.1) 
1 Includes butter/margarines from fried vegetables, potatoes and baking 
2 Includes milk and milk products and cheese 
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Table 3. Linear regression analyses 
          
  Partial r1 P-value1 Partal r2 P-value2 
COWAT 0.114 <0.001 0.055 0.021 
KOLT 0.077 0.001 0.049 0.041 
m-DST 0.079 0.001 0.00 0.930 
m-MMSE 0.052 0.022 0.01 0.649 
TMT-A -0.02 0.304 0.02 0.493 
m-BD 0.04 0.075 0.00 0.857 
Z-scores 0.103 <0.001 0.03 0.246 
1 Adjusted for sex 
2 Adjusted for sex, ApoE ε4 variant allele, education, tHcy and total energy 
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Table 4. Risk for poor cognitive performance by quintiles of vitamin D intake 
          
  n = 1761 Intake of vitamin D by quintiles OR1 95% CI for OR 
COWAT     
 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.68 0.39, 1.16 
 358 5.96 - 9.19 0.74 0.43, 1.28 
 360 3.58 - 5.95 0.94 0.56, 1.59 
 322 ≤ 3.57 1.10 0.73, 2.29 
P-trend   0.318  
KOLT     
 365 ≥ 15.63 ref  
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 356 9.20 - 15.62 0.89 0.52, 1.48 
 358 5.96 - 9.19 1.00 0.59, 1.68 
 360 3.58 - 5.95 0.71 0.41, 1.26 
 322 ≤ 3.57 1.81 1.04, 3.15 
P-trend   0.161  
m-DST     
 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.76 0.38, 1.50 
 358 5.96 - 9.19 1.31 0.70, 2.45 
 360 3.58 - 5.95 1.27 0.68, 2.37 
 322 ≤ 3.57 1.55 0.79, 3.05 
P-trend   0.092  
m-MMSE     
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 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.39 0.19, 0.79 
 358 5.96 - 9.19 0.95 0.54, 1.67 
 360 3.58 - 5.95 0.94 0.54, 1.66 
 322 ≤ 3.57 0.88 0.47, 1.64 
P-trend   0.609  
TMT-A     
 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.79 0.46, 1.36 
 358 5.96 - 9.19 1.20 0.73, 2.00 
 360 3.58 - 5.95 0.91 0.53, 1.54 
 322 ≤ 3.57 0.78 0.43, 1.41 
P-trend   0.636  
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m-BD     
 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.83 0.53, 1.31 
 358 5.96 - 9.19 0.80 0.50, 1.26 
 360 3.58 - 5.95 0.74 0.46, 1.17 
 322 ≤ 3.57 0.94 0.58, 1.53 
P-trend   0.605  
Z-scores     
 365 ≥ 15.63 ref  
 356 9.20 - 15.62 0.96 0.55, 1.67 
 358 5.96 - 9.19 1.19 0.69, 2.05 
 360 3.58 - 5.95 0.94 0.53, 1.65 
 322 ≤ 3.57 1.31 0.72, 2.37 
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P-trend     0.477   
1 Adjusted for sex, ApoE ε4 variant allele, education, tHcy and total energy intake 
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Table 5. Binomial logistic regression analysis showing risk of scoring poorly on the KOLT as a result of decreased intake of lean and fatty 
fish with the population divided into users/non-users of cod liver oil. 
                
   User (n = 672)  Non-user (n = 1089) 
    n OR 95% CI n OR 95% CI 
KOLT        
Lean Fish ≥ 50.1 g/d 198 ref  270 ref  
 25.1 - 50.0 g/d 242 0.76 0.36, 1.60 385 0.98 0.55, 1.74 
 0.1 - 25.0 g/d 194 1.23 0.57, 2.63 345 1.92 1.08, 3.43 
 0.0 g/d 38 0.71 0.15, 3.44 89 1.82 0.83, 3.99 
P-trend1   0.845   0.016  
        
Fatty Fish ≥ 20.1 g/d 204 ref  266 ref  
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 10.1 - 20.0 g/d 165 0.74 0.77, 3.95 235 0.74 0.40, 1.38 
 0.1 - 10.0 g/d 216 1.47 0.64, 3.38 368 0.90 0.52, 1.57 
 0.0 g/d 87 1.87 0.69, 5.04 220 1.06 0.58, 1.69 
P-trend1     0.255     0.743   
        
1 Adjusted for sex, ApoE ε4 variant allele, education, plasma tHcy, total energy intake and mutually for fatty or lean fish intake 
Table 1S. Mean and median intakes of vitamin D from different food groups stratified by intake of cod liver oil, and the relative 
contribution of vitamin D intake from the different food groups. 
              
 Non-user (n = 1206) User (n = 710) 
  Mean (SD) 
Median (25th 
and 75th 
percentiles) 
Mean 
percent 
contribution 
(SD) Mean (SD) 
Median (25th 
and 75th 
percentiles) 
Mean 
percent 
contribution 
(SD) 
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Vitamin D total (µg/d) 6.0 (4.1) 5.2 (3.1, 7.8)  17.0 (8.9) 3 15.5 (10.1, 23.9)  
Supplements total   4.4 (14.7)   55.7 (24.8) 
Total intake (g/d) 0.3 (1.4) 0 (0, 0)  5.0 (4.1)3 5.1 (1.7, 6.5)  
Vitamin D (µg/d) 0.4 (1.6) 0 (0, 0)  10.6 (8.1) 11.0 (4.1, 15.1)  
Cod liver oil   –   50.8 (25.7) 
Total intake (g/d) – –  4.5 (3.5) 5.1 (1.4, 5.6)  
Vitamin D (µg/d) – –  9.7 (7.5) 11.0 (3.0, 12.1)  
Supplements rest   4.4 (14.7)   4.9 (12.3) 
Food intake (g/d) 0.3 (1.4) 0 (0, 0)  0.5 (1.9)4 0 (0, 0)  
Vitamin D (µg/d) 0.4 (1.6) 0 (0, 0)  0.9 (2.6) 0 (0, 0)  
Fish total    46.4 (24.0)   24.7 (18.3) 
Food intake (g/d) 83.2 (52.9) 74.9 (44.9, 111)  98.7 (58.3)3 90.6 (59.2, 125)  
Vitamin D (µg/d) 3.1 (3.1) 2.3 (1.0, 4.2)  3.8 (3.3) 2.9 (1.4, 5.2)  
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Fatty fish   27.4 (22.7)   14.9 (14.3) 
Food intake (g/d) 13.6 (16.7) 8.2 (2.1, 19.4)  16.6 (16.9) 3 11.3 (3.5, 24.0)  
Vitamin D (µg/d) 1.9 (2.4) 1.2 (0.3, 2.8)  2.4 (2.4) 1.6 (0.5, 3.4)  
Lean fish   4.1 (4.08)   1.8 (1.8) 
Food intake (g/d) 34.4 (27.5) 27.5 (15.0, 48.9)  40.3 (32.0) 3 34.1 (17.8, 53.8)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3)  0.2 (0.2) 0.2 (0.1, 0.3)  
Fish rest   14.9 (14.6)   8.0 (8.9) 
Food intake (g/d) 35.2 (27.7) 30.3 (16.0, 46.9)  41.9 (31.1) 3 36.5 (23.0, 52.9)  
Vitamin D (µg/d) 1.0 (1.4) 0.5 (0.1, 1.4)  1.2 (1.6) 0.8 (0.2, 1.7)  
Butter/margarines1   40.3 (21.4)   16.6 (13.2) 
Food intake (g/d) 55.9 (37.5) 48.1 (28.4, 75.2)  63.9 (37.8) 3 57.9 (36.0, 81.8)  
Vitamin D (µg/d) 1.7 (1.1) 1.5 (0.9, 2.4)  1.8 (1.2) 1.6 (0.8, 2.5)  
Egg   5.3 (5.7)   1.7 (1.7) 
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Food intake (g/d) 16.0 (11.9) 15.3 (7.7, 19.4)  15.4 (10.8)4 15.4 (7.7, 19.4)  
Vitamin D (µg/d) 0.2 (0.2) 0.2 (0.1, 0.3)  0.2 (0.2) 0.2 (0.1, 0.3)  
Dairy products2   3.2 (3.5)   1.1 (1.1) 
Food intake (g/d) 328 (203) 301 (180, 435)  367 (208) 3 346 (217, 485)  
Vitamin D (µg/d) 0.1 (0.1) 0.1 (0.1, 0.1)   0.1 (0.1) 0.1 (0.1, 0.2)   
1 Includes butter/margarines from fried vegetables, potatoes and baking     
2 Includes milk and milk products and cheese      
3 ANOVA adjusted for sex. Significant at P<0.001      
4 ANOVA adjusted for sex. Not significant      
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Table 2S. Student’s T-test on dichotomous variables in reference to cognitive test scores and vitamin D intake  
  Sex ApoE CVD Diabetes 
  
Mean 
difference1 P-value3 
Mean 
difference2 P-value 
Mean 
difference2 P-value 
Mean 
difference2 P-value 
COWAT -0.04 0.862 -0.25 0.347 -0.57 0.035 -1.72 0.001 
KOLT -3.19 <0.001 -1.19 0.002 -1.67 <0.001 -1.66 0.024 
m-DST 0.15 0.44 -0.52 0.012 -0.21 0.323 -0.91 0.021 
m-MMSE 0.03 0.32 -0.1 0.011 -0.05 0.184 -0.1 0.132 
TMT-A -3.47 0.019 3.19 0.055 3.05 0.057 3.13 0.299 
m-BD 0.14 0.16 -0.03 0.776 -0.12 0.261 -0.2 0.327 
Z-score -0.06 0.171 -0.13 0.007 -0.16 0.001 -0.29 0.002 
Vitamin D 2.96 <0.001 0.25 0.529 -0.09 0.821 -0.53 0.493 
1 Men - women       
 124 
2 Sick - healthy        
3 P-value from Student's t-test       
 
             125 
Table 3S. Simple correlations between continuous covariates, the cognitive tests and vitamin D intake 
                    
  n COWAT KOLT m-DST m-MMSE TMT-A m-BD Z-score Vitamin D 
Vitamin D 1916 0.12** 0.03 0.08** 0.05* -0.05* 0.04 0.10** 1.000 
Education 1779 0.33** 0.11** 0.42** 0.20** -0.27** 0.17** 0.40** 0.15** 
tHcy 1911 -0.06** -0.14** -0.06* -0.04 0.07** -0.02 -0.11** -0.05* 
BMI 1913 -0.05* -0.05* -0.03 -0.02 -0.02 -0.02 -0.05* -0.04 
Depression score 1793 -0.06* -0.10** -0.10** -0.01 0.10** -0.04 -0.12** -0.03 
Smoking 1916 0.00 -0.01 -0.03 -0.02 0.07** -0.07** -0.05* 0.03 
Creatinine 1909 0.03 -0.10** 0.01 0.03 -0.05* 0.05* 0.00 0.09* 
Systolic blood pressure 1916 -0.051* 0.006 -0.036 -0.047* 0.014 0.005 -0.031 -0.013 
Diastolic blood pressure 1916 -0.032 -0.023 -0.015 -0.002 -0.039 0.021 0.000 0.048* 
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Total energy 1916 0.06* -0.03 0.06* 0.04 -0.01 0.05* 0.05* 0.48** 
          
Supplements 1916 0.12** 0.05* 0.07** 0.04 -0.05* 0.04 0.10** 0.75** 
Fish 1916 0.05* 0.05* 0.07** 0.07** -0.07** 0.07** 0.09** 0.53** 
Fatty 1916 0.06** 0.06** 0.06** 0.03 -0.06** 0.03 0.08** 0.50** 
Lean and medium 1916 0.02 0.06** 0.04 0.08** -0.05* 0.06* 0.07** 0.29** 
Butter/oils1 1916 0.02 -0.05 0.06** 0.04 -0.04 0.07** 0.05* 0.35** 
Eggs 1916 -0.00 0.0.3 -0.05* 0.02 0.01 -0.02 -0.04 0.12** 
Dairy products2 1916 -0.05* -0.02 -0.09** -0.02 0.08** 0.02 -0.07** 0.14** 
Fruit3 1916 0.13** 0.12** 0.14** 0.08** -0.09** 0.10** 0.18** 0.23** 
Meat and meat products 1916 0.06** 0.01 0.07** 0.07** -0.03 0.07** 0.07** 0.31** 
Cereals4 1916 0.07** 0.03 0.09** 0.05* -0.10** 0.11** 0.11** 0.22** 
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Vegetables5 1916 0.11** 0.09** 0.112** 0.11** -0.09** 0.05* 0.15** 0.25** 
Sweets 1916 0.09** 0.04 0.10** 0.02 -0.05* 0.07** 0.11** 0.15** 
Drinks          
Tea 1916 0.10** 0.09** 0.13** 0.09** -0.11** 0.05* 0.16** 0.06* 
Wine 1916 0.23** 0.14** 0.23** 0.15** -0.17** 0.09** 0.27** 0.16** 
* P<0.05          
** P<0.001          
1 Butter/margarines including from baking and fried onions and fried potatoes 
2 Dairy products including milk and milk products and cheese 
3 Fruit + juice 
4 Cereals with pizza extracted 
5 Vegetables with fried onions extracted
Appendices 
Appendix I  Consent form 
Appendix II  Hordaland Health Study; questionnaire 1 
Appendix III  Invitation letter 
Appendix IV  Hordaland Health Study; food frequency questionnaire 
Appendix V  Hordaland Health Study; cognitive testing 
Appendix VI  Hospital Anxiety and Depression Scale 
 
 


12. ARBEID
Tok du noen slags medisiner I GÅR?...............................
Hvis NEI, kan du gå til avsnitt 12.
Hvis JA, besvar følgende:
Hvilke medisiner tok du I GÅR, og hva var grunnen til at du tok
medisinen (diagnose, sykdom, symtom, helseeffekt)?
Sett svarene inn i skjemaet nedenfor, en linje for hver medisin.
Kryss av for ja om du bruker medisinen daglig eller nesten daglig.
Dersom det ikke er nok plass her, kan du fortsette på eget ark som legges ved.
Oppgi antall egne barn (eventuelt 0) av hvert kjønn:
Antall gutter Antall jenter
11. BRUK AV MEDISINER
NEI
Personlig innbydelse
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I HORDALAND 1997-99
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Hvor ofte i løpet av de siste 4 ukene
har du hatt mye overskudd? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg nedfor og trist? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
I løpet av de siste 4 ukene, hvor mye av tiden har din fysiske
helse eller følelsesmessige problemer påvirket din sosiale
omgang(som det å besøke venner, slekt)? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
Stort sett, vil du si at din helse er:
Utmerket Meget god God Nokså god Dårlig
1 2 3 4 5
Med medisiner mener vi her alle slags medisiner, både:
• med og uten resept, naturmedisin, vitaminer og mineraler
• medisin som svelges, inhaleres eller injiseres, stikkpiller,
salver, kremer eller dråper.
Navn på medisinen
(ett navn pr. linje):
Grunn til bruk av medisinen
I GÅR var:
Daglig
JA      NEI
Hvor lenge har du praktisert
i dette yrket i ditt liv? ...........................
Besvares av dem som har hatt inntektsgivende arbeid i minst 100 timer det siste året:
Beskriv virksomheten på det arbeidsstedet der du utførte
inntektsgivende arbeid i lengst tid de siste 12 mnd. (Skriv f.eks.
jordbruk, barneavd. på sykehus, snekkeravd. på skipsverft e.l.).
Virksomhet:
Antall år i yrket
Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet?
(Skriv f.eks. kornbonde, anestesisykepleier, snekker e.l.)
Yrke:
Har du noen av de følgende yrker (heltid eller deltid)?
Sett kryss for hvert spørsmål.
Sjåfør ................................................................................
Bonde/gårdbruker.............................................................
Fisker................................................................................
NEIJA
Har du tidligere i ditt llv (ikke i dag) hatt inntektsgivende
arbeid som:
Bilmekaniker/biloppretter ..................................................
Frisør ................................................................................
NEIJA
13. SAMLIV
Har du noen gang hatt regelmessig samliv uten pre-
vensjon i ett år eller mer uten at det har ført til graviditet?...
Med prevensjon menes også mer usikre metoder
som avbrutt samleie, «sikre perioder» etc.
NEIJA
Hvis denne helseundersøkelsen viser at du bør undersøkes
nærmere, hvilken allmennpraktiserende lege/kommunelege
ønsker
Ikke skriv i disse rutene
14. ETTERUNDERSØKELSE
Takk for utfyllingen!
Nok en gang:         Velkommen til undersøkelsen
1
2
3
4
5
6
1
2
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6
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4
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Adresse endring
JA
Har du noen gang spontanabortert (ufrivillig mistet fosteret)
etter at graviditet var sikkert påvist?
Hvis JA:
Antall ganger
Følgende spørsmål besvares bare hvis du har vært gravid:
Oppgi antall måneder det tok med regelmessig samliv
uten prevensjon (eller evt. amming), til du ble gravid:
Siste svangerskap ....................
Nest siste svangerskap.............
Tredje siste svangerskap ..........
USIKKER JANEI
mnd. uten prevensjon
mnd. uten prevensjon
mnd. uten prevensjon
De følgende spørsmål besvares bare av kvinner
Nei/ubetydelig I noen grad I betydelig grad Vet ikke
1. EGEN HELSE 4. MUSKEL- OG SKJELETTPLAGER
Hvordan er helsen din nå? (Sett bare ett kryss)
Dårlig Ikke helt god God Svært god
Har du, eller har du hatt:
Hjerteinfarkt.....................................................
Angina pectoris (hjertekrampe).......................
Hjerneslag/hjerneblødning ..............................
Astma ..............................................................
Diabetes (sukkersyke).....................................
Multippel sklerose ...........................................
Har du de siste to ukene følt deg:
Nervøs og urolig? ............
Plaget av angst?..............
Trygg og rolig?.................
Irritabel? ..........................
Glad og optimistisk?........
Nedfor/deprimert? ...........
Ensom? ...........................
Nei
Med «hvite fingre» mener vi plager i form av at en eller
flere fingre blir hvite og at man samtidig mister følelsen
i dem når det er kaldt. Har du slike plager?.....................
Har en eller flere av foreldre eller søsken
hatt hjerteinfarkt (sår på hjertet) eller
angina pectoris (hjertekrampe)? ..............................
Har en eller flere foreldre/søsken hatt:
Hjerteinfarkt før de fylte 60 år?.................................
Hjerneslag/hjerneblødning før de fylte 70 år? ..........
Har du i løpet av det siste året vært plaget med
smerter og/eller stivhet i muskler og ledd som
har vart i minst 3 måneder sammenhengende?..............
Hvis NEI, gå til avsnitt 5.
Hvis JA, svar på følgende:
Hvor har du hatt disse plagene?
Nakke ...............................................................................
Skuldre (aksler) ................................................................
Albuer ...............................................................................
Håndledd/hender..............................................................
Bryst, mage ......................................................................
Øvre del av ryggen ...........................................................
Korsryggen .......................................................................
Hofter................................................................................
Knær.................................................................................
Ankler, føtter .....................................................................
Hvor lenge har plagene vart sammenhengende?
Svar for det området hvor plagene har vart lengst.
Hvis under 1 år, oppgi antall måneder............Antall mnd.
Hvis 1 år eller mer, oppgi antall år ......................Antall år
Har du noen gang det siste året hatt eksem
(rød, kløende, sår og sprukken hud):
På hendene? ....................................................................
I ansiktet? .........................................................................
Andre steder på kroppen?................................................ Har plagene redusert din arbeidsevne det siste året?
Gjelder også hjemmearbeidende. Sett bare ett kryss.
Har du vært sykmeldt p.g.a. disse
plagene det siste året? ..............................................
Har plagene ført til redusert aktivitet i fritiden? ......
1 2 3 4
1 2 3 4
Litt
En god
del
Svært
mye
Bruker du medisin mot høyt blodtrykk?
Nå Før, men ikke nå Aldri brukt
1 2 3
1 2 3 4
T i m e r  p r . u k e
NEI
Alder første
gang
JA
NEIJA
NEIJA
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål på grunn av din fysiske helse?
Du har utrettet mindre enn du hadde ønsket ....................
Du har vært hindret i å utføre visse typer
arbeid eller gjøremål .........................................................
NEIJA
I løpet av de siste 4 ukene, har du hatt noen av de
følgende problemer i ditt arbeid eller i andre av dine
daglige gjøremål p.g.a. følelsesmessige problemer?
(Som f.eks. å være deprimert eller engstelig)
Du har utrettet mindre enn du hadde ønsket ....................
Du har utført arbeidet eller andre gjøremål
mindre grundig enn vanlig ................................................
NEIJA
I løpet av de siste 4 ukene, hvor mye har
smerter påvirket ditt vanlige arbeid?
(Gjelder både i og utenfor hjemmet) Sett bare ett kryss.
Ikke i det hele tatt .............................................................
Litt.....................................................................................
En del ...............................................................................
Mye...................................................................................
Svært mye ........................................................................
JA
Hvor ofte i løpet av de siste 4 ukene
har du følt deg rolig og harmonisk? Sett bare ett kryss.
Hele tiden .........................................................................
Nesten hele tiden .............................................................
Mye av tiden .....................................................................
En del av tiden..................................................................
Litt av tiden .......................................................................
Ikke i det hele tatt .............................................................
JA
NEIJA
NEI
VET
IKKEJA
NEI
Ikke i
arbeidJA
NEIJA
år
år
år
år
år
år
3. SYKDOM I FAMILIEN
2. HVORDAN FØLER DU DEG?
Hvilken utdanning er den høyeste du har fullført?
Sett bare ett kryss.
Mindre enn 7 år grunnskole..............................................
Grunnskole 7-10 år, framhaldsskole,
folkehøgskole....................................................................
Realskole,  middelskole, yrkesskole,
1-2 årig videregående skole .............................................
Artium, øk.gymnas, allmennfaglig retning
i videregående skole ........................................................
Høgskole/universitet, mindre enn 4 år ..............................
Høgskole/universitet, 4 år eller mer ..................................
De neste spørsmålene handler om hvordan du ser på
din egen helse. Hvis du er usikker på hva du skal svare,
vennligst svar så godt du kan.
Er din helse slik at den begrenser deg i utførelsen
av disse aktivitetene NÅ? 
Hvor mange kopper kaffe/te drikker du daglig?
Sett 0 hvis du ikke drikker kaffe/te daglig.
A n t a l l  k o p p e r  d a g l i g
Kokekaffe       Annen kaffe             Te
Er du total avholdsmann/-kvinne?....................................
Hvor mange ganger i måneden drikker du
vanligvis alkohol? Regn ikke med lettøl.
Sett 0 hvis mindre enn 1 gang i mnd.............Antall ganger
Hvor mange glass øl, vin eller brennevin
drikker du VANLIGVIS i løpet av to uker?
Regn ikke med lettøl. Sett 0 hvis du ikke drikker alkohol.
NEIJA
NEI
6. KAFFE / TE / ALKOHOL
5. MOSJON
Eksempler:
Avkryssing: Tall: Bokstaver:
1
2
3
4
5
Glass
øl
Glass
vin
Glass
brennevin
9. UTDANNING
Hvor lenge er du vanligvis daglig
tilstede i røykfylt rom?.............................Antall hele timer
Sett 0 hvis du ikke oppholder deg i røykfylt rom.
Røyker du selv:
Sigaretter daglig? .............................................................
Sigarer/sigarillos daglig? ..................................................
Pipe daglig?......................................................................
Aldri røykt daglig ....................
Hvordan har din fysiske aktivitet i fritiden vært
det siste året?
Tenk deg et ukentlig gjennomsnitt for året.
Arbeidsvei regnes som fritid. Besvar begge spørsmålene.
Dette gjelder din interesse
for å endre helsevaner.
Røykespørsmålet besvares
bare av dem som røyker.
Har du de siste 12 mnd. forsøkt å:
Om 5 år, tror du at du har
endret vaner på noen av
disse områdene?.............................
Anslå din høyeste og laveste vekt
i løpet av de siste 5 år. (Hele kg)
(Se bort fra vekt under svangerskap)
NEIJA NEIJA NEIJA
NEIJA NEIJA NEIJA
8. ENDRING AV HELSEVANER
10. HELSE OG TRIVSEL
7. RØYKING
1 2 3 4
Høyeste
vekt
Spise
sunnere
Trimme
mer
Slutte
å røyke
Laveste
vekt
Hvis du har røykt daglig tidligere, hvor
lenge er det siden du sluttet?..............................Antall år
Hvis du røyker daglig nå eller har røykt tidligere:
Hvor mange sigaretter røyker eller 
røykte du vanligvis daglig? ......................Antall sigaretter
Hvor gammel var du da du begynte 
å røyke daglig? ..................................................Alder i år
Hvor mange år til sammen har 
du røykt daglig? ..................................................Antall år
(Sett kryss)
JA
Under 1 1-2 3 og merLett aktivitet
(ikke svett/andpusten) .....
Hard fysisk aktivitet
(svett/andpusten) ............
Ingen
S
Det utfylte skjemaet vil bli lest av en maskin. Bruk blå eller sort farge ved utfylling. Det er viktig at du går fram slik:
• i de små boksene setter du kryss for det svaret som passer best for deg
• i de store boksene skriver du tall eller blokkbokstaver – NB! innenfor rammen for boksen.
pørreskjemaet er en viktig del av helseundersøkelsen. Vennligst fyll ut skjemaet på forhånd og ta det med til helseundersøkelsen. Dersom
enkelte spørsmål er uklare, lar du dem stå ubesvart til du møter fram, og drøfter dem med personalet som gjennomfører undersøkelsen.
Alle svar vil bli behandlet strengt fortrolig.
x
Moderate aktiviteter som å flytte bord, støvsuge, gå
en tur eller drive med hagearbeid:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
Gå opp trappen flere etasjer:
Ja, begrenser Ja, begrenser Nei, begrenser meg
meg mye meg litt ikke i det hele tatt
1
2
3
4
5
1
2
3
4
5
6
Med vennligh hilsen
Statens helseundersøkelser Kommunehelsetjenesten  Helseundersøkelsen i Hordaland

HVA SPISER DU?
I dette skjemaet spør vi om dine spisevaner slik de vanligvis er.
Vi er klar over at kostholdet varierer fra dag til dag. Prøv derfor 
så godt du kan å gi et "gjennomsnitt" av dine spisevaner. Ha det
siste året i tankene når du fyller ut skjemaet. Der du er usikker,
anslå svaret.
Skjemaet skal leses av en maskin, og derfor er det viktig at du
setter et tydelig kryss i avmerket rute.
Riktig markering er slik:
Bruk helst bløt blyant. Feil kan da rettes med viskelær.
Kulepenn og svart tusjpenn kan også brukes.
Av hensyn til den maskinelle lesingen pass på at arkene ikke blir brettet.
Alle svar vil bli behandlet strengt fortrolig.
EKSEMPEL PÅ UTFYLLING AV SPØRSMÅL 1.
Kari Nordmann spiser daglig 5 skiver brød og ett
knekkebrød. Hun spiser vanligvis kneippbrød, men i helgene
blir det en del loff. I tillegg spiser hun ett knekkebrød hver
dag. Hun fyller ut første spørsmål slik:
1.HVOR MYE BRØD PLEIER DU Å SPISE?
Legg sammen det du bruker til alle måltider i løpet av en dag.
(1/2 rundstykke = 1 skive, 1 baguett = 5 skiver, 1 ciabatta = 4 skiver)
Fint brød
(loff, baguetter, fine rundstykker o.l.)
Mellomgrovt brød
(lys helkorn, lys kneipp, lyst hj.bakt o.l.)
Grovt brød
(fiberkneipp, mørk kneipp, mørkt hj.bakt o.l.)
Knekkebrød
(kavring, grov skonrok o.l.)
0 1/2 1 2 3 4 5 6 7 8 9 10 11 12+
Antall skiver pr. dag
Sum skiver pr. dag = ____
Antall skiver pr. uke: _______ = ____  Tallet brukes i spørsmål 5.
6
6 x 7 42
2.HVA PLEIER DU Å SMØRE PÅ 
BRØDET?
Merk av både for hverdag og helg, selv
om du bruker det samme.
3.OM DU BRUKER 
FETT PÅ BRØD, HVOR
MYE BRUKER DU?
4.MELK SOM DRIKK
(1 glass = 1,5 dl)
1.HVOR MYE BRØD PLEIER DU Å SPISE?
Legg sammen det du bruker til alle måltider i løpet av en dag.
(1/2 rundstykke = 1 skive, 1 baguett = 5 skiver, 1 ciabatta = 4 skiver)
Fint brød
(loff, baguetter, fine rundstykker o.l.)
Mellomgrovt brød
(lys helkorn, lys kneipp, lyst hj.bakt o.l.)
Grovt brød
(fiberkneipp, mørk kneipp, mørkt hj.bakt o.l.)
Knekkebrød
(kavring, grov skonrok o.l.)
0 1/2 1 2 3 4 5 6 7 8 9 10 11 12+
Antall skiver pr. dag
Sum skiver pr. dag = ____
Antall skiver pr. uke: ____ x 7 = ____. Tallet brukes i spørsmål 5.
Hverdager Lørdager, søndager En porsjonspakning på 12 g
rekker til antall skiver
Bruker ikke
1/2 1 2 3 4 5 6 7 8+
Drikker
sjelden/
ikke
Antall glass pr. dag
1
5
4
3
2
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3
Smør   (meierismør)
Bremykt, Smøregod
Brelett
Soft, soyamargarin (pakke, beger)
Solsikke
Oliven
Vita
Olivero
Omega
Soft light
Vita lett
Annen margarin
Helmelk, søt, sur
Lettmelk, søt, sur
Lettmelk, ekstra lett
Skummet melk, søt, sur
61852
5.PÅLEGGSSORTER
Bruk sum skiver pr. uke fra spørsmål 1.
Brun ost, prim
Hvit ost, helfet, 27% fett (Jarlsberg,
Norvegia o.l., smøreost; eske, tube)
Hvit ost, halvfet, 16% fett (Jarlsberg,
Norvegia o.l., smøreost; eske, tube)
Ost med mer enn 27% fett
(kremoster, Normanna, Ridderost)
Leverpostei, vanlig
Leverpostei, mager
Servelat, vanlig
Lett servelat, kalverull,
kokt skinke, okserull o.l.
Salt pølse, spekepølse
(fårepølse, salami o.l.)
Kaviar
Sardiner, sursild, ansjos o.l.
Makrell i tomat, røkt makrell
Laks, ørret
Syltetøy, marmelade, frysetøy
Reker, krabbe
Honning, sirup,
sjokolade-, nøttepålegg
Majones på smørbrød
Grønnsaker som pålegg
(agurk, tomat o.l.)
Frukt som pålegg (banan, eple o.l.)
Salater med majones
(kokt, stekt, eggerøre, omelett)
6.EGG
0
Til antall skiver pr. uke
1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 enn 1 1 3-4 5-6 7 8+2
Mindre Antall pr. uke
4
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8. KAFFE OG TE
(1 kopp kaffe = 1,2 dl    1 kopp te = 2 dl)
7. FROKOSTGRYN, GRØT OG YOGHURT
Svar enten pr. måned eller pr. uke. <1 betyr sjeldnere enn 1 gang.
Melk søt, sur på gryn,
grøt og dessert
Havregryn, kornblandinger
(4-korn, usøtet müsli o.l.)
Cornflakes, puffet ris,
havrenøtter o.l.
Havregrøt
Sukker til frokostgryn, grøt
Yoghurt, naturell, frukt
Lettyoghurt
Go´morgen yoghurt
inkl. müsli
Kaffe, kokt
Kaffe, traktet, filter
Kaffe, pulver (instant)
Kaffe, koffeinfri
Te
Nypete, urtete
Sukker til kaffe
Sukker til te
Fløte til kaffe
Kunstig søtstoff til kaffe eller te
0 1/2 1 2 3
Antall teskjeer eller biter pr. kopp
4+
1/2 1 3-42 5-6
Antall kopper pr. dag
7-8
Drikker
ikke/ikke
daglig 9-10 11+
2-3
Gang pr. måned Gang pr. uke Mengde pr. gang
4-5 6-7 8+1321<10
1 1 1/2 2 3+
1 1 1/2 2 3+
1-2 3-4 5-6 7+
1 2 3-4 5+
1/2 1 1 1/2 2+
1/2 1 1 1/2 2+
1/2 1 1 1/2 2+
3/4 1 2 3+
(dl)
(dl)
(dl)
(ts)
(beger)
(beger)
(beger)
(dl)
5
Taco (med kjøtt og salat)
Pastaretter
Alkoholfritt øl, vørterøl,
lettøl
Kjøttdeigretter (saus eller gryte
med kjøttdeig, lasagne o.l.)
9. ANDRE DRIKKER?
Svar enten pr. måned eller pr. uke.  < 1 betyr sjeldnere enn 1 gang.
Merk at porsjonsenhetene er forskjellige. 1/3 liter tilsvarer en halvflaske øl 
og 2/3 liter tilsvarer en helflaske.
Vann
Appelsinjuice
Annen juice, most, nektar
Saft, solbærsirup
m. sukker
Saft, kunstig søtet
Brus, Cola, Solo o.l.,
med sukker
Brus, Cola, Solo o.l.,
kunstig søtet
Farris, Selters, Soda o.l.
Pilsnerøl
Vin
Brennevin, likør
Kjøttpølse, medisterpølse
Hamburger, karbonader o.l.
Grill- og wienerpølse
Kjøttkaker, medisterkaker,
kjøttpudding
Hamburger-, pølsebrød,
lomper
2
Gang pr. måned
1<10 3 4 5-6 7-8 9+
(kjøttpølse)
(stk)
(pølse)
(stk)
(stk)
(dl)
(stk)
(dl)
Gang pr. måned Gang pr. uke Mengde pr. gang
0 <1 1 2 3 1 2-3 4-5 6-7 8+
(glass)
(glass)
(glass)
(glass)
(glass)
(liter)
(liter)
(liter)
(liter)
(liter)
(glass)
(1 dram
= 4 cl)
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1 2 3 4 5
1 2 3 4 5
5+
5+
5+
5+
5+
11/2+
11/2+
11/2+
6+
6+
11/2+
11/2+
61852
10. MIDDAGSRETTER
Vi spør både om middagsmåltidene og det du spiser til andre måltider. Tell til slutt
sammen antall retter du har merket for og se om summen virker sannsynlig.
En "dl" tilsvarer omtrent mengden i en suppeøse. Med "ss" menes en spiseskje.
Mengde pr. gang
1/2 2/3 1 2+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
11/2
6
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Pizza (500-600 g)
Koteletter (lam, okse, svin)
Biff (alle typer kjøtt)
Stek (elg, hjort, reinsdyr o.l.)
Stek (lam, okse, svin)
Gryterett med helt kjøtt,
frikassé, fårikål o.l.
Lapskaus, suppelapskaus,
betasuppe
Bacon, stekt flesk
Kylling, høne
Torsk, sei, hyse (kokt)
Leverretter
Fiskekaker, fiskepudding,
fiskeboller
Fiskepinner
Torsk, sei, hyse (stekt, panert)
Sild (fersk, speket, røkt)
Makrell (fersk, røkt)
Laks, ørret (sjø, oppdrett)
Fiskegryte, -grateng, suppe
med fisk
Reker, krabbe
Risgrøt, annen melkegrøt
Pannekaker
Suppe (tomat, blomkål,
ertesuppe o.l.)
Vegetarrett, vegetarpizza
grønnsakgrateng, -pai
Brun/hvit saus
Smeltet margarin, smør
til fisk
Bearnaisesaus o.l.
Majones, remulade
Ketchup
2
Gang pr. måned
(pizza)
(stk)
(stk)
(skive)
(skive)
(dl)
(dl)
(skive)
(stk)
(skive)
(kake)
(stk)
(stk)
(stk)
(filet)
(filet)
(skive)
(dl)
(dl, renset)
(dl)
(stk)
(dl)
(bit/dl)
(dl)
(ss)
(ss)
(ss)
(ss)
Mengde pr. gang
1<10 3 4 5-6 7-8 9+
1/8 1/4 1/2 3/4 1+
21<10 3 4 5-6 7-8 9+
21<10 3 4 5-6 7-8 9+
21<10 3 4 5-6 7-8 9+
1/2 1 1 1/2 2 2 1/2+
1-2 3-4 5-6 7-8 9+
1/4 1/3 1/2 3/4 1+
1 2 3 4 5+
1/2 1 1 1/2 2 3+
1-2 3-4 5-6 7-8 9+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1/2 1 1 1/2 2 2 1/2+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-9 10+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1/2 1 1 1/2 2 2 1/2+
7
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11. POTETER, RIS, SPAGHETTI, GRØNNSAKER
Svar enten pr. måned eller pr. uke. <1 betyr sjeldnere enn 1 gang.
Disse spørsmålene dreier seg først og fremst om tilbehør til middagsretter, men
spiser du for eksempel en rå gulrot eller salat til lunsj, skal det tas med her. 
0
Gang pr. måned Gang pr. uke Mengde pr. gang
<1 1 2 3 1 2-3 4-5 6-7 8+
Poteter, kokte
Pommes frites, stekte
poteter
Potetmos, -stuing,
gratinerte poteter
Ris
Spaghetti, makaroni,
pasta
Gulrot
Hodekål
Kålrot
Blomkål
Brokkoli
Rosenkål
Grønnkål
Løk
Spinat, andre bladgrønns.
Sopp
Avocado
Paprika
Tomat
Tomatbønner, bønner/linser
Mais
Erter, frosne grønnsak-
blandinger
Salatblandinger
Dressing
Rømme
Hvor mange ganger om dagen spiser du vanligvis
grønnsaker utenom grønnsakene du spiser til middag?
(stk)
(dl)
(dl)
(dl)
(dl)
(stk)
(skalk)
(skive)
(bukett)
(bukett)
(stk)
(dl)
(ss)
(dl)
(stk)
(stk)
(strimmel)
(stk)
(dl)
(ss)
(dl)
(dl)
(ss)
(ss)
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1/2 1 2 3 4+
1/2 1 2 3 4+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1/2 1 1 1/2 2 3+
1/4 1/2 3/4 1 1 1/4 +
1/2 1 1 1/2 2 3+
0 1 2 3 4 5+
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12. TYPE FETT TIL MATLAGING
13. FRUKT
Svar enten pr. måned eller pr. uke. < 1 betyr sjeldnere enn 1 gang.
Hvor mange frukter spiser du vanligvis pr. dag? 0 1 2 3 4 5 6
9
Smør (meierismør)
Bremykt
Melange, Per
Soft-, soyamargarin (pakke, beger)
Solsikke
Oliven
Olivenolje
Soyaolje
Maisolje
Solsikkeolje
Valnøttolje
Andre oljer
Annen margarin
Smør/margarin Oljer
Mengde pr. gang
Eple 0
Appelsin, mandarin,
grapefrukt
Banan
Druer
Eksotisk frukt (kiwi, mango)
Annen frukt (fersken,
pære m.v.)
Jordbær, bringebær
(friske, frosne)
Blåbær
Gang pr. måned Gang pr. uke
<1 1 2 3 1 2-3 4-5 6-7 8+
(stk)
(stk)
(stk)
(klase)
(stk)
(stk)
(dl)
(dl)
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
Multer (dl)
1/2 1 2 3+
7 8 9+
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14. DESSERT, KAKER, GODTERI
Svar enten pr. måned eller pr. uke. < 1 betyr sjeldnere enn 1 gang.
Hermetisk frukt, fruktgrøt
Puddinger (sjokolade,
karamell o.l.)
Is (1 dl = 1 pinne = 1
kremmerhus)
Boller, julekake, kringle
Skolebrød, skillingsbolle
Wienerbrød, -kringle o.l.
Smultring, formkake
Vafler
Sjokoladekake, bløtkake,
annen fylt kake
Søt kjeks, kakekjeks
(Cookies, Bixit, Hob Nobs)
Sjokolade (60 g)
Drops, lakris, seigmenn o.l.
Smågodt (1 hg = 100g)
Potetgull (1 pose 100g = 7 dl)
Annen snacks (skruer, crisp,
saltstenger, lettsnacks o.l.)
Peanøtter, andre nøtter
(1 pose 100g = 4 never)
Gang pr. måned Gang pr. uke Mengde pr. gang
0 <1 1 2 3 1 2-3 4-5 6-7 8+
(dl)
(dl)
(dl)
(stk)
(stk)
(stk)
(stk)
(stk)
(stk)
(stk)
(plate)
(plate)
(hg)
(dl)
(dl)
(neve)
1/2 3+21
1/2 3+21
1/2 3+21
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1-2 7+5-63-4
1-2 7+5-63-4
1-2 7+5-63-4
1-2 7+5-63-4
1/2 1 1/2+13/4
1/2 3+21
10
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15. KOSTTILSKUDD (bs = barneskje, ts = teskje)
Tran
Trankapsler
Fiskeoljekapsler
Multipreparater
Sanasol
Biovit
Vitaplex
Kostpluss
Vitamineral
Annet
Jernpreparater
Ferro C
Hemofer
Duroferon
Duretter
Annet
B-vitaminer
C-vitamin
D-vitamin
E-vitamin
Folat (folsyre)
Kalktabletter
Fluortabletter
Annet
Hvis annet, hvilket? ..................................................................
Hvis annet, hvilket? ..................................................................
Hvis annet, hvilket? ..................................................................
Gang pr. uke
6-7
Mengde pr. gang
4-52-31<10
6-74-52-31<10
6-74-52-31<10
6-74-52-31<10
6-74-52-31<10
kapsler
kapsler
bs
bs
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
1 ts 1 bs 1 ss
1 2+
1-2 3-4 5-6 7+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
Hele
året
Bare vinter-
halvåret
11
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16. NÅR SPISER DU PÅ HVERDAGER?
17. MENER DU SVARENE I SPØRRESKJEMAET GIR
ET BRUKBART BILDE AV KOSTHOLDET DITT?
18. ER DU FORNØYD MED KROPPSVEKTEN DIN SLIK DEN ER NÅ?
19. KJØNN
Vennligst se etter at du har svart på alle spørsmål.
Takk for innsatsen!
HOVEDMÅLTIDER som frokost, formiddagsmat, middag, kvelds.
MELLOMMÅLTIDER som kaffe, frukt, godteri, snacks m.v.
Er det matvarer/produkter du regelmessig bruker, og som ikke er nevnt i skjemaet?
.................................................................................................................................
.................................................................................................................................
6 8 10 12 14 16 18 20 22 24 2 4
6 8 10 12 14 16 18 20 22 24 2 4
Ja Nei
Ja
Nei, jeg ønsker å slanke meg
Nei, jeg ønsker å legge på meg
Mann Kvinne
Omtrent klokken
Omtrent klokken
12
HUSK DELPROSJEKT: HUKOMMELSE OG MINNE
1. Hvilket år er det?
2. Hvilken måned er det?
3. Hvilken dato er det i dag?
4. Hvilken dag er det i dag?
5. I hvilken landsdel er vi nå?
6. Hva er postnummeret ditt?
7. Be pasienten stave ordet SVERD baklengs. Gi ett
poeng hvis det er tre eller flere riktige
bokstaver sagt i rett rekkefølge.
8. Kan du si meg de ordene du skulle huske for litt
siden? (OST - SYKKEL - BOK).
Gi ett poeng hvis pasienten klarer minst ett ord.
9. Gjenta følgende setning: «Aldri annet
enn om og men».
10. Utfør følgende: Ta et stykke papir med din
høyre hånd, brett det over på midten, og legg
det på gulvet.
Gi ett poeng hvis alt er gjort riktig.
11. Skriv en setning.
(skal inneholde subjekt og predikat).
12. Kopier denne tegningen.
Intervjuer:
Symbol Digit Modalities Test
Kendrick
Generating first names
Block design
Trail making
Total skår
Si 3 ord, OST - SYKKEL - BOK, langsomt,
1 sekund mellom hver. Be pasienten gjenta dem
etter deg til han/hun har lært dem. Ikke gi poeng her.
Skår
Maksimal
skår
Skår
Maksimal
skår
1
1
1
1
1
1
1
1
1
1
1
1
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HAD 
 
Rettledning 
Her kommer noen spørsmål om hvorledes du føler seg. For hvert spørsmål setter du 
kryss for ett av de fire svarene som best beskriver dine følelser den siste uken.  
Ikke tenk for lenge på svaret – de spontane svarene er best. 
            
            
            
            
            
            
            
            
            
             
 
 
            
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  Jeg føler meg nervøs og urolig 
2.   Jeg gleder meg fortsatt over  
      tingene slik jeg pleide før 
  0 –Avgjort like mye 
  1 –Ikke fullt så mye 
  2 –Bare lite grann 
  3 –Ikke i det hele tatt 
 
  3 –Mesteparten av tiden 
  2 –Mye av tiden
  1 –Fra tid til annen 
  0 –Ikke i det hele tatt 
 
3.   Jeg har en urofølelse som om  
      noe forferdelig vil skje 
  3 –Ja, og noe svært ille 
  2 –Ja, ikke så veldig ille 
  1 –Litt, bekymrer meg lite 
  0 –Ikke i det hele tatt 
 
4.   Jeg kan le og se det morsomme 
      i situasjoner  
  0 –Like mye nå som før 
  1 –Ikke like mye nå som før 
  2 –Avgjort ikke som før 
  3 –Ikke i det hele tatt 
 
5. Jeg har hodet fullt av bekymringer 
  3 –Veldig ofte 
  2 –Ganske ofte 
  1 –Av og til  
  0 –En gang i blant 
 
6.   Jeg er i godt humør 
  3 –Aldri 
  2 –Noen ganger 
  1 –Ganske ofte    
  0 –For det meste 
 
7.   Jeg kan sitte i fred og ro 
      og kjenne meg avslappet 
  0 –Ja, helt klart 
  1 –Vanligvis 
  2 –Ikke så ofte 
  3 –Ikke i det hele tatt 
 
8.   Jeg føler meg som om alt   
      går langsommere 
  3 –Nesten hele tiden 
  2 –Svært ofte 
  1 –Fra tid til annen 
  0 –Ikke i det hele tatt 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.   Jeg føler meg urolig som om  
      jeg har sommerfugler i magen  
  0 –Ikke i det hele tatt 
  1 –Fra tid til annen 
  2 –Ganske ofte 
  3 –Svært ofte 
 
10.  Jeg bryr meg ikke lenger 
       om hvordan jeg ser ut 
  
  3 –Ja, jeg har sluttet å bry meg 
  2 –Ikke som jeg burde 
  1 –Kan hende ikke nok 
  0 –Bryr meg som før 
 
11.  Jeg er rastløs som om  
       jeg stadig må være aktiv 
  
  3 –Uten tvil svært mye 
  2 –Ganske mye 
  1 –Ikke så veldig mye 
  0 –Ikke i det hele tatt 
 
12.  Jeg ser med glede frem til  
       hendelser og ting 
  
  0 –Like mye som før 
  1 –Heller mindre enn før 
  2 –Avgjort mindre enn før 
  3 –Nesten ikke i det hele tatt 
 
13.  Jeg kan plutselig få en  
       følelse av panikk 
  
  3 –Uten tvil svært ofte 
  2 –Ganske ofte 
  1 –Ikke så veldig ofte 
  0 –Ikke i det hele tatt 
 
14.  Jeg kan glede meg over  
       gode bøker, radio og TV 
  
  0 –Ofte 
  1 –Fra tid til annen 
  2 –Ikke så ofte 
  3 –Svært sjelden 
 

  
